(dp1
S'10.1016/j.ijid.2006.09.010'
p2
(lp3
S'nasal vaccine candidate'
p4
aS'nasal vaccine'
p5
aS'healthy adults'
p6
aS'adverse events were'
p7
aS'7 15 30'
p8
aS'30 and 60'
p9
aS'0 7 15'
p10
aS'Adverse events were'
p11
aS'nasal'
p12
aS'trial'
p13
aS'HBsAg and HBcAg'
p14
aS'hepatitis B virus'
p15
aS'data collection sheets'
p16
aS'placebo group'
p17
aS'anti HBc antibodies'
p18
aS'30 days after'
p19
aS'anti HBs antibody'
p20
asS'10.1016/0163-7258(88)90016-2'
p21
(lp22
S'temperature regulation'
p23
aS'evidence'
p24
aS'system theoretical'
p25
aS'temperature regulation adaptation'
p26
aS'adaptation'
p27
aS'regulation adaptation'
p28
aS'Complementary system theoretical'
p29
aS'temperature'
p30
aS'Complementary'
p31
aS'system'
p32
aS'regulation'
p33
aS'fever Complementary'
p34
aS'theoretical'
p35
aS'fever'
p36
aS'experimental evidence'
p37
aS'mechanisms'
p38
aS'adaptation and fever'
p39
asS'10.1016/j.jada.2006.08.007'
p40
(lp41
S'gestational weight gain'
p42
aS'excessive gestational weight'
p43
aS'prenatal nutrition interventions'
p44
aS'inadequate and excessive'
p45
aS'Social Cognitive Theory'
p46
aS'excessive gestational'
p47
aS'education and counseling'
p48
aS'appropriate gestational weight'
p49
aS'Institute of Medicine'
p50
aS'both inadequate'
p51
aS'among pregnant adolescents'
p52
aS'nutrition education'
p53
aS'uoi B758G 4M9NHJD'
p54
aS'prenatal nutrition'
p55
aS'among pregnant teens'
p56
aS'effect on birth'
p57
aS'highest risk'
p58
asS'10.1016/j.clinthera.2006.05.008'
p59
(lp60
S'6 month'
p61
aS'blind placebo controlled'
p62
aS'randomized double blind'
p63
aS'month randomized double'
p64
aS'double blind placebo'
p65
aS'6 month randomized'
p66
aS'sibutramine in obese'
p67
aS'sibutramine'
p68
aS'sibutramine group'
p69
aS'group at end'
p70
aS'placebo group'
p71
aS'obese Mexican adolescents'
p72
aS'placebo'
p73
aS'diet and exercise'
p74
aS'05 for all'
p75
aS'sibutramine group changed'
p76
aS'2 95 CI'
p77
asS'10.1016/0305-0491(75)90014-0'
p78
(lp79
S'Alaskan king crab'
p80
aS'1 6 diphosphatase'
p81
aS'000 mol wt'
p82
aS'Alaskan king'
p83
aS'mol wt subunits'
p84
aS'single form'
p85
aS'40 000'
p86
aS'Alaskan'
p87
aS'pI'
p88
aS'functional differences between'
p89
aS'subunits from both'
p90
aS'sodium dodecyl sulfate'
p91
aS'values of pI'
p92
aS'halves by exposure'
p93
aS'altered to yield'
p94
aS'isoenzyme during thermal'
p95
aS'two 66 000'
p96
asS'x'
(lp97
S'Alaskan king crab'
p98
aS'1 6 diphosphatase'
p99
aS'000 mol wt'
p100
aS'Alaskan king'
p101
aS'mol wt subunits'
p102
aS'single form'
p103
aS'40 000'
p104
aS'Alaskan'
p105
aS'pI'
p106
aS'functional differences between'
p107
aS'subunits from both'
p108
aS'sodium dodecyl sulfate'
p109
aS'values of pI'
p110
aS'halves by exposure'
p111
aS'altered to yield'
p112
aS'isoenzyme during thermal'
p113
aS'two 66 000'
p114
aS'dissociation into small'
p115
aS'were around 25'
p116
aS'2 sodium dodecyl'
p117
aS'sucrose density gradient'
p118
aS'subunits were around'
p119
aS'around 25 000'
p120
aS'cold and warm'
p121
aS'40 000 mol'
p122
aS'4 4 Exposure'
p123
aS'66 000 mol'
p124
aS'around 135 000'
p125
aS'judged by ultracentrifugation'
p126
aS'warm acclimatized animal'
p127
aS'000 as judged'
p128
aS'wt subunits differed'
p129
aS'mol wt halves'
p130
aS'halves of FDPase'
p131
aS'presumably underlie functional'
p132
aS'40 000 respectively'
p133
aS'underlie functional differences'
p134
aS'000 and 40'
p135
aS'25 000 mol'
p136
aS'unequal molecular weight'
p137
aS'4 M urea'
p138
aS'new isoenzyme during'
p139
aS'loss of activity'
p140
aS'dissociated into two'
p141
aS'weight of around'
p142
aS'dodecyl sulfate results'
p143
aS'subunits of unequal'
p144
aS'during thermal acclimatization'
p145
aS'subunits differed markedly'
p146
aS'cold acclimatized animal'
p147
aS'FDPase from skeletal'
p148
aS'isoelectric point pI'
p149
aS'1 1 Fructose'
p150
aS'6 diphosphatase FDPase'
p151
aS'king crab occurs'
p152
aS'pI of about'
p153
aS'enzyme'
p154
aS'cold'
p155
aS'warm'
p156
aS'molecular weight'
p157
aS'small'
p158
aS'identical'
p159
aS'25 000'
p160
aS'single'
p161
aS'40'
p162
aS'identical while'
p163
aS'presumably underlie'
p164
aS'native enzyme'
p165
aS'warm acclimatized'
p166
aS'complete loss'
p167
aS'enzyme molecule'
p168
aS'sucrose density'
p169
aS'pI values'
p170
aS'around 135'
p171
aS'further dissociation'
p172
aS'warm FDPases'
p173
aS'ultracentrifugation through'
p174
aS'thermal isoenzymes'
p175
aS'small portion'
p176
aS'symmetrically arranged'
p177
aS'small subunits'
p178
aS'2 sodium'
p179
aS'physical differences'
p180
aS'two 66'
p181
aS'subunits were'
p182
aS'new isoenzyme'
p183
aS'unequal molecular'
p184
aS'results suggest'
p185
aS'perhaps only'
p186
aS'cold acclimatized'
p187
aS'pI value'
p188
aS'skeletal muscle'
p189
aS'isoelectric point'
p190
aS'halves'
p191
aS'FDPase'
p192
aS'around'
p193
aS'molecular'
p194
aS'results'
p195
aS'values'
p196
aS'muscle'
p197
aS'25'
p198
aS'thermal'
p199
aS'symmetrically'
p200
aS'dissociated'
p201
aS'ultracentrifugation'
p202
aS'presumably'
p203
aS'complete'
p204
aS'sucrose'
p205
aS'further'
p206
aS'new'
p207
aS'native'
p208
aS'two'
p209
aS'unequal'
p210
aS'perhaps'
p211
aS'founded'
p212
aS'judged'
p213
aS'yield'
p214
aS'appears'
p215
aS'both'
p216
aS'activity'
p217
aS'physical'
p218
aS'altered'
p219
aS'exposure'
p220
aS'weights'
p221
aS'isoelectric'
p222
aS'skeletal'
p223
aS'about'
p224
aS'subunits'
p225
aS'isoenzymes'
p226
aS'000'
p227
aS'000 mol'
p228
aS'mol'
p229
aS'wt'
p230
aS'mol wt'
p231
aS'weight'
p232
aS'king'
p233
aS'crab'
p234
aS'king crab'
p235
aS'wt subunits'
p236
aS'diphosphatase'
p237
aS'6 diphosphatase'
p238
aS'form'
p239
aS'acclimatized'
p240
aS'animal'
p241
aS'acclimatized animal'
p242
aS'differences'
p243
aS'through'
p244
aS'135'
p245
aS'during'
p246
aS'differed'
p247
aS'around 25'
p248
aS'loss'
p249
aS'isoenzyme during'
p250
aS'sodium dodecyl'
p251
aS'gradient'
p252
aS'subunits differed'
p253
aS'functional differences'
p254
aS'sodium'
p255
aS'dodecyl'
p256
aS'wt halves'
p257
aS'density gradient'
p258
aS'while'
p259
aS'molecule'
p260
aS'dissociation'
p261
aS'density'
p262
aS'sulfate'
p263
aS'were around'
p264
aS'urea'
p265
aS'M urea'
p266
aS'66 000'
p267
aS'dodecyl sulfate'
p268
aS'between'
p269
aS'respectively'
p270
aS'sulfate results'
p271
aS'000 respectively'
p272
aS'66'
p273
aS'markedly'
p274
aS'during thermal'
p275
aS'underlie'
p276
aS'only'
p277
aS'differed markedly'
p278
aS'FDPases'
p279
aS'arranged'
p280
aS'isoenzyme'
p281
aS'were'
p282
aS'differences between'
p283
aS'suggest'
p284
aS'portion'
p285
aS'Exposure'
p286
aS'thermal acclimatization'
p287
aS'functional'
p288
aS'135 000'
p289
aS'4 Exposure'
p290
aS'underlie functional'
p291
aS'acclimatization'
p292
aS'value'
p293
aS'diphosphatase FDPase'
p294
aS'1 Fructose'
p295
aS'occurs'
p296
aS'point pI'
p297
aS'point'
p298
aS'Fructose'
p299
aS'crab occurs'
p300
aS'emph'
p301
aS'subunit'
p302
aS'seasonal isoenzymes'
p303
aS'seasonal'
p304
aS'value of 58'
p305
aS'subunit structure'
p306
aS'diphosphatase from muscle'
p307
aS'52'
p308
aS'structure of seasonal'
p309
aS'about 52'
p310
aS'crab emph typestyle'
p311
aS'58'
p312
aS'Paralithodes camtschatica'
p313
aS'camtschatica emph'
p314
aS'emph typestyle'
p315
aS'king crab emph'
p316
aS'camtschatica'
p317
aS'typestyle'
p318
aS'isoenzymes of fructose'
p319
aS'Paralithodes'
p320
aS'Paralithodes camtschatica emph'
p321
aS'fructose'
p322
aS'structure'
p323
aS'crab emph'
p324
asS'10.1037/0003-066X.33.9.821'
p325
(lp326
S'psychotherapy research'
p327
aS'psychotherapy'
p328
aS'need to control'
p329
aS'authors suggest'
p330
aS'placebo'
p331
aS'inert procedure without'
p332
aS'control for such'
p333
aS'ref PsycINFO Database'
p334
aS'available therapies component'
p335
aS'placebo effect rubric'
p336
aS'condition being treated'
p337
aS'without specific activity'
p338
aS'contact and therapist'
p339
aS'term placebo group'
p340
aS'controls in psychotherapy'
p341
aS'discussed 26 ref'
p342
aS'psychotherapy placebo group'
p343
asS'10.1016/S0002-8223(95)00279-0'
p344
(lp345
S'receiving nutrition advice'
p346
aS'prenatal care'
p347
aS'mothers reported receiving'
p348
aS'Live Birth File'
p349
aS'advice by maternal'
p350
aS'Infant Death File'
p351
aS'breast feeding'
p352
aS'prenatal'
p353
aS'mothers receiving'
p354
aS'among live births'
p355
aS'maternal characteristics among'
p356
aS'Table 1 Percent'
p357
aS'n 9 639'
p358
aS'mothers receiving nutrition'
p359
aS'characteristics among live'
p360
aS'weighted of mothers'
p361
aS'1 Percent weighted'
p362
asS'10.1016/S0306-4565(01)00023-7'
p363
(lp364
S'semi supine'
p365
aS'cutaneous blood flow'
p366
aS'evaporative heat loss'
p367
aS'course of mean'
p368
aS'temperature regulation'
p369
aS'semi supine posture'
p370
aS'Student s paired'
p371
aS'supine and semi'
p372
aS'SEM Difference between'
p373
aS'supine and supine'
p374
aS'regulation in humans'
p375
aS'semi'
p376
aS'selective brain cooling'
p377
aS'than in semi'
p378
aS'both postural conditions'
p379
aS'influence'
p380
aS'than in supine'
p381
asS'10.1016/S0188-4409(03)00069-9'
p382
(lp383
S'body fat pattern'
p384
aS'low income'
p385
aS'incidence and progression'
p386
aS'body fat'
p387
aS'grade 1 obesity'
p388
aS'overweight and obesity'
p389
aS'body mass index'
p390
aS'progression of obesity'
p391
aS'Mexico'
p392
aS'first follow up'
p393
aS'obesity'
p394
aS'mean waist circumference'
p395
aS'follow up phases'
p396
aS'Mexico City'
p397
aS'fat pattern distribution'
p398
aS'Mexican population'
p399
aS'99 70 44'
p400
asS'10.1016/0305-0491(74)90071-6'
p401
(lp402
S'tanner crab'
p403
aS'1 6 diphosphatase'
p404
aS'tanner crab muscle'
p405
aS'crab muscle FDPase'
p406
aS'tanner'
p407
aS'temperature'
p408
aS'tanner crab over'
p409
aS'high approaching physiological'
p410
aS'concentrations of AMP'
p411
aS'increase in affinity'
p412
aS'approaching physiological concentrations'
p413
aS'rise in pH'
p414
aS'sensitivity for AMP'
p415
aS'activity of FDPase'
p416
aS'inhibitor of activity'
p417
aS'regulation of muscle'
p418
aS'activity of tanner'
p419
asS'd'
(lp420
S'nasal vaccine candidate'
p421
aS'nasal vaccine'
p422
aS'healthy adults'
p423
aS'adverse events were'
p424
aS'7 15 30'
p425
aS'30 and 60'
p426
aS'0 7 15'
p427
aS'Adverse events were'
p428
aS'nasal'
p429
aS'trial'
p430
aS'HBsAg and HBcAg'
p431
aS'hepatitis B virus'
p432
aS'data collection sheets'
p433
aS'placebo group'
p434
aS'anti HBc antibodies'
p435
aS'30 days after'
p436
aS'anti HBs antibody'
p437
aS'50 g HBcAg'
p438
aS'50 g HBsAg'
p439
aS'Source data collection'
p440
aS'healthy'
p441
aS'day 30'
p442
aS'trial in healthy'
p443
aS'core antigens'
p444
aS'seroconversion in 100'
p445
aS'proportion of subjects'
p446
aS'vaccine'
p447
aS'HBsAg HBcAg vaccine'
p448
aS'HBcAg vaccine candidate'
p449
aS'60 days'
p450
aS'day 90 75'
p451
aS'HBs and anti'
p452
aS'9 8 palate'
p453
aS'9 8 headache'
p454
aS'34 1 rhinorrhea'
p455
aS'included sneezing 34'
p456
aS'8 palate itching'
p457
aS'2 nasal stuffiness'
p458
aS'12 2 nasal'
p459
aS'1 rhinorrhea 12'
p460
aS'mild in intensity'
p461
aS'events were recorded'
p462
aS'were recorded during'
p463
aS'anti HBc'
p464
aS'study'
p465
aS'anti HBc seroconversion'
p466
aS'well tolerated'
p467
aS'nasal route'
p468
aS'12h 24h 48h'
p469
aS'24h 48h 72h'
p470
aS'6h 12h 24h'
p471
aS'events were actively'
p472
aS'were actively recorded'
p473
aS'via nasal spray'
p474
aS'hepatitis B vaccine'
p475
aS'19 healthy male'
p476
aS'were randomly allocated'
p477
aS'systemic adverse events'
p478
aS'healthy male adults'
p479
aS'physiologic saline solution'
p480
aS'day 90'
p481
aS'CIGB Havana Cuba'
p482
aS'nasal co administration'
p483
aS'immunization schedule'
p484
aS'placebo'
p485
aS'HBs antibody levels'
p486
aS'Source data'
p487
aS'first'
p488
aS'B virus HBV'
p489
aS'safety and immunogenicity'
p490
aS'events were defined'
p491
aS'local adverse events'
p492
aS'events were reported'
p493
aS'clinical trial'
p494
aS'50'
p495
aS'responders anti HBs'
p496
aS'total'
p497
aS'day'
p498
aS'HBsAg HBcAg'
p499
aS'hepatitis B vaccines'
p500
aS'Center for Genetic'
p501
aS'Genetic Engineering Biotechnology'
p502
aS'strong immunogenicity'
p503
aS'clinical'
p504
aS'HBcAg and HBsAg'
p505
aS'45 years'
p506
aS'immunogenicity of HBcAg'
p507
aS'HBcAg'
p508
aS'route with 50'
p509
aS'g HBsAg following'
p510
aS'linked to 50'
p511
aS'HBcAg HBsAg vaccine'
p512
aS'response to HBcAg'
p513
aS'HBsAg vaccine candidate'
p514
aS'HBcAg non covalently'
p515
aS'candidate in healthy'
p516
aS'healthy volunteers immunized'
p517
aS'phase'
p518
aS'Center for Toxicology'
p519
aS'J Finlay Hospital'
p520
aS'Carlos J Finlay'
p521
aS'doses per study'
p522
aS'Frequency of each'
p523
aS'number of applied'
p524
aS'applied doses per'
p525
aS'per study group'
p526
aS'event with respect'
p527
aS'type of adverse'
p528
aS'well'
p529
aS'60'
p530
aS'severe'
p531
aS'vaccine candidate'
p532
aS'hepatitis'
p533
aS'vaccine recipients'
p534
aS'chronic'
p535
aS'nasal wash'
p536
aS'0 5ml'
p537
aS'chronic HBV infected'
p538
aS'19 healthy'
p539
aS'any'
p540
aS'World Health Organization'
p541
aS'results'
p542
aS'nasal co'
p543
aS'HBsAg'
p544
aS'subjects'
p545
aS'systemic adverse'
p546
aS'any other'
p547
aS'written informed consent'
p548
aS'immunization'
p549
aS'mice'
p550
aS'chronic infection'
p551
aS'adverse event'
p552
aS'other'
p553
aS'two'
p554
aS'vaccine group'
p555
aS'anti HBs'
p556
aS'Genetic Engineering'
p557
aS'chronic HBV'
p558
aS'volunteers'
p559
aS'immunogenic'
p560
aS'mixture of 50'
p561
aS'axillary temperature'
p562
aS'core'
p563
aS'immunity'
p564
aS'more than'
p565
aS'general malaise'
p566
aS'30 days'
p567
aS'systemic'
p568
aS'100'
p569
aS'systemic immunity'
p570
aS'anti'
p571
aS'each'
p572
aS'local adverse'
p573
aS'animal'
p574
aS'full length'
p575
aS'knowledge'
p576
aS'anti HBs titers'
p577
aS'events were mild'
p578
aS'safe'
p579
aS'applied doses'
p580
aS'placebo group withdrew'
p581
aS'study group'
p582
aS'virus'
p583
aS'patients with chronic'
p584
aS'intensity'
p585
aS'candidate comprising HBV'
p586
aS'study in healthy'
p587
aS'demonstration of safety'
p588
aS'safe well tolerated'
p589
aS'comprising HBV antigens'
p590
aS'tolerated and immunogenic'
p591
aS'vaccine candidate comprising'
p592
aS'unexpected events were'
p593
aS'using corresponding ELISA'
p594
aS'vaccine elicited anti'
p595
aS'tolerated Adverse reactions'
p596
aS'seroprotective anti HBs'
p597
aS'well tolerated Adverse'
p598
aS'dose Anti HBs'
p599
aS'elicited anti HBc'
p600
aS'each dose Anti'
p601
aS'after each dose'
p602
aS'titers were evaluated'
p603
aS'severe or unexpected'
p604
aS'reactions included sneezing'
p605
aS'per nostril Adverse'
p606
aS'early as day'
p607
aS'kits at days'
p608
aS'1h 6h 12h'
p609
aS'anti HBc titers'
p610
aS'recorded 1h 6h'
p611
aS'immunization schedule while'
p612
aS'100 of subjects'
p613
aS'were evaluated using'
p614
aS'nostril Adverse events'
p615
aS'actively recorded 1h'
p616
aS'evaluated using corresponding'
p617
aS'intensity No severe'
p618
aS'corresponding ELISA kits'
p619
aS'HBs titer 10IU'
p620
aS'days and 30'
p621
aS'days after each'
p622
aS'HBc titers were'
p623
aS'safe and well'
p624
aS'75 All subjects'
p625
aS'subjects as early'
p626
aS'placebo group remained'
p627
aS'30 and 90'
p628
aS'72h 7 days'
p629
aS'90 75 All'
p630
aS'8 and general'
p631
aS'group remained seronegative'
p632
aS'remained seronegative during'
p633
aS'maximum at day'
p634
aS'anti HBs titer'
p635
aS'limiting and mild'
p636
aS'reactions were all'
p637
aS'were all self'
p638
aS'all self limiting'
p639
aS'Adverse reactions included'
p640
aS'placebo via nasal'
p641
aS'five dose schedule'
p642
aS'administered in two'
p643
aS'0 9 physiologic'
p644
aS'9 physiologic saline'
p645
aS'NASVAC comprising hepatitis'
p646
aS'vaccine candidate NASVAC'
p647
aS'HBV surface HBsAg'
p648
aS'double blinded placebo'
p649
aS'profile of nasal'
p650
aS'safety and immunogenic'
p651
aS'candidate NASVAC comprising'
p652
aS'core antigens HBcAg'
p653
aS'HBV recombinant antigens'
p654
aS'administration of both'
p655
aS'randomized clinical trial'
p656
aS'markers of immunity'
p657
aS'both HBV recombinant'
p658
aS'according to Good'
p659
aS'guidelines Participants ranged'
p660
aS'immunogenic in animal'
p661
aS'HBsAg and core'
p662
aS'18 to 45'
p663
aS'infection to HBV'
p664
aS'aimed at exploring'
p665
aS'years and were'
p666
aS'allocated to receive'
p667
aS'Practice guidelines Participants'
p668
aS'Good Clinical Practice'
p669
aS'placebo controlled randomized'
p670
aS'ranged in age'
p671
aS'Clinical Practice guidelines'
p672
aS'blinded placebo controlled'
p673
aS'age from 18'
p674
aS'controlled randomized clinical'
p675
aS'virus HBV surface'
p676
aS'Source'
p677
aS'pre and post'
p678
aS'saliva and nasal'
p679
aS'nasal wash samples'
p680
aS'anterior and posterior'
p681
aS'covalently linked'
p682
aS'HBcAg HBsAg'
p683
aS'Antibody response'
p684
aS'healthy volunteers'
p685
aS'National Center'
p686
aS'Accuspray Becton Dickinson'
p687
aS'five'
p688
aS'full length HBcAg'
p689
aS'19'
p690
aS'each type'
p691
aS'total number'
p692
aS'concentration of anti'
p693
aS'reactions were'
p694
aS'more than 10IU'
p695
aS's exact test'
p696
aS'Fisher s exact'
p697
aS'also'
p698
aS'both'
p699
aS'early'
p700
aS'mean anti HBs'
p701
aS'confidence intervals were'
p702
aS'95 confidence intervals'
p703
aS'adverse events included'
p704
aS'linked immunosorbent assay'
p705
aS'enzyme linked immunosorbent'
p706
aS'C and any'
p707
aS'require medical attention'
p708
aS'may require medical'
p709
aS'combined to give'
p710
aS'age'
p711
aS'recombinant'
p712
aS'strong'
p713
aS'adverse events'
p714
aS'administered'
p715
aS'performed'
p716
aS'seroprotective'
p717
aS'respect'
p718
aS'administration'
p719
aS'studied'
p720
aS'mucosal'
p721
aS'unexpected'
p722
aS'patients'
p723
aS'saliva'
p724
aS'double blinded'
p725
aS'approximately'
p726
aS'were randomly'
p727
aS'adverse'
p728
aS'dose schedule'
p729
aS'World Health'
p730
aS'used'
p731
aS'time'
p732
aS'related'
p733
aS'HBV'
p734
aS'participants'
p735
aS'safety'
p736
aS'had'
p737
aS'45'
p738
aS'90'
p739
aS'local'
p740
aS'HBV antigens'
p741
aS'Phase'
p742
aS'most'
p743
aS'first inoculation'
p744
aS'nasal spray'
p745
aS'mixture'
p746
aS'more'
p747
aS'infected patients'
p748
aS'co'
p749
aS'immunogenicity'
p750
aS'populations'
p751
aS'control'
p752
aS'Genetic'
p753
aS'antiviral'
p754
aS'schedule'
p755
aS'addition'
p756
aS'nasal mucosa'
p757
aS'carried'
p758
aS'adults'
p759
aS'dose'
p760
aS'second'
p761
aS'immune'
p762
aS'post immunization'
p763
aS'access'
p764
aS'immune system'
p765
aS'second dose'
p766
aS'Center'
p767
aS'geometric mean'
p768
aS'further'
p769
aS'antigens'
p770
aS'Preclinical'
p771
aS'antibody responses'
p772
aS'relevant'
p773
aS'recorded during'
p774
aS'demonstrated'
p775
aS'vaccine formulation'
p776
aS'devices'
p777
aS'self'
p778
aS'general'
p779
aS'proportion'
p780
aS'serum'
p781
aS'T cell'
p782
aS'study prior'
p783
aS'all'
p784
aS'Figure'
p785
aS'antigen'
p786
aS'days'
p787
aS'full'
p788
aS'detection'
p789
aS'high'
p790
aS'subjects reporting'
p791
aS'18'
p792
aS'mild'
p793
aS'safe well'
p794
aS'first demonstration'
p795
aS'vaccine elicited'
p796
aS'seroprotective anti'
p797
aS'unexpected events'
p798
aS'days 30'
p799
aS'placebo via'
p800
aS'five dose'
p801
aS'two dosages'
p802
aS'total volume'
p803
aS'highly immunogenic'
p804
aS'serologic markers'
p805
aS'immunity infection'
p806
aS'animal models'
p807
aS'performed according'
p808
aS'immunogenic profile'
p809
aS'both HBV'
p810
aS'Good Clinical'
p811
aS'applied'
p812
aS'covalently'
p813
aS'Antibody'
p814
aS'National'
p815
aS'Toxicology'
p816
aS'Carlos'
p817
aS'Anti HBc'
p818
aS'experiments'
p819
aS'immunity against'
p820
aS'95'
p821
aS'Frequency'
p822
aS'participants inoculated'
p823
aS'purified'
p824
aS'were'
p825
aS'data collection'
p826
aS'other nasal'
p827
aS'study nurse'
p828
aS'order'
p829
aS'vaccine were'
p830
aS'shown'
p831
aS'95 confidence'
p832
aS'EM analysis'
p833
aS'development'
p834
aS'sensitivity'
p835
aS'carriers'
p836
aS'single'
p837
aS'responders'
p838
aS'infected'
p839
aS'commercial'
p840
aS'30'
p841
aS'formulation'
p842
aS'75'
p843
aS'Anti'
p844
aS'each dose'
p845
aS'protein'
p846
aS'screening'
p847
aS'reactions'
p848
aS'combined'
p849
aS'Havana'
p850
aS'15'
p851
aS'fourth'
p852
aS'Th1'
p853
aS'same'
p854
aS'7 days'
p855
aS'6h 12h'
p856
aS'undertaken'
p857
aS'axillary'
p858
aS'events'
p859
aS'third'
p860
aS'group'
p861
aS'antibody'
p862
aS'required'
p863
aS'negative'
p864
aS'6h'
p865
aS'need'
p866
aS'increase'
p867
aS'World'
p868
aS'infection'
p869
aS'licensed hepatitis'
p870
aS'double'
p871
aS'frequency'
p872
aS'72h'
p873
aS'headache'
p874
aS'recombinant HBcAg'
p875
aS'All'
p876
aS'sneezing'
p877
aS'achieved'
p878
aS'very'
p879
aS'all participants'
p880
aS'candidate'
p881
aS'one'
p882
aS'induced'
p883
aS'Cuba'
p884
aS'participants were'
p885
aS'reported'
p886
aS'spray'
p887
aS'evaluated'
p888
aS'hematology'
p889
aS'primary'
p890
aS'recorded'
p891
aS'potential'
p892
aS'positive'
p893
aS'elicited'
p894
aS'events were'
p895
aS'tolerated'
p896
aS'revealed'
p897
aS'samples'
p898
aS'licensed'
p899
aS'staff'
p900
aS'device'
p901
aS'data'
p902
aS'collection'
p903
aS'written informed'
p904
aS'recording'
p905
aS'use'
p906
aS'125'
p907
aS'EM'
p908
aS'analysis'
p909
aS'sera'
p910
aS'10IU'
p911
aS'baseline'
p912
aS'successive'
p913
aS'route'
p914
aS'HBc'
p915
aS'HBs'
p916
aS'titers'
p917
aS'developed'
p918
aS'blinded'
p919
aS'blood'
p920
aS'seroprotection'
p921
aS'after'
p922
aS'profile'
p923
aS'days after'
p924
aS'15 30'
p925
aS'7 15'
p926
aS'seroconversion'
p927
aS'vaccines'
p928
aS'B vaccines'
p929
aS'according'
p930
aS'using'
p931
aS'against'
p932
aS'against HBV'
p933
aS'HBV infection'
p934
aS'hypo'
p935
aS'Engineering'
p936
aS'Engineering Biotechnology'
p937
aS'Biotechnology'
p938
aS'volunteer'
p939
aS'nasal adverse'
p940
aS'than'
p941
aS'type'
p942
aS'HBcAg vaccine'
p943
aS'response'
p944
aS'commercial anti'
p945
aS'subjects were'
p946
aS'10'
p947
aS'Adverse'
p948
aS'Adverse events'
p949
aS'rhinorrhea'
p950
aS'stuffiness'
p951
aS'nasal stuffiness'
p952
aS'itching'
p953
aS'palate itching'
p954
aS'palate'
p955
aS'considered'
p956
aS'studies'
p957
aS'abnormalities'
p958
aS'responses against'
p959
aS'responses'
p960
aS'clinically'
p961
aS'self limiting'
p962
aS'limiting'
p963
aS'obtained'
p964
aS'without'
p965
aS'treatment'
p966
aS'planned'
p967
aS'observation period'
p968
aS'doses'
p969
aS'titer'
p970
aS'remained'
p971
aS'group remained'
p972
aS'surface'
p973
aS'system'
p974
aS'present'
p975
aS'geometric'
p976
aS'90 75'
p977
aS'inoculation'
p978
aS'specific'
p979
aS'were mild'
p980
aS'per'
p981
aS'Havana Cuba'
p982
aS'post'
p983
aS'hyper responder'
p984
aS'basic'
p985
aS'g HBcAg'
p986
aS'g HBsAg'
p987
aS'12h'
p988
aS'Participants'
p989
aS'corresponding'
p990
aS'resulted'
p991
aS'event'
p992
aS'during'
p993
aS'seronegative'
p994
aS'standard'
p995
aS'enough'
p996
aS'included sneezing'
p997
aS'2 nasal'
p998
aS'sneezing 34'
p999
aS'12'
p1000
aS'8 palate'
p1001
aS'8 headache'
p1002
aS'34'
p1003
aS'1 rhinorrhea'
p1004
aS'rhinorrhea 12'
p1005
aS'included'
p1006
aS'malaise'
p1007
aS'remaining'
p1008
aS'any local'
p1009
aS'rates'
p1010
aS'24h'
p1011
aS'sample'
p1012
aS'administered HBsAg'
p1013
aS'activity'
p1014
aS'human'
p1015
aS'epistaxis'
p1016
aS'were more'
p1017
aS'HBV vaccine'
p1018
aS'following'
p1019
aS'sterile'
p1020
aS'B virus'
p1021
aS'randomized'
p1022
aS'sera were'
p1023
aS'recipients'
p1024
aS'solution'
p1025
aS'years'
p1026
aS'were recorded'
p1027
aS'maximum'
p1028
aS'highly'
p1029
aS'exploring'
p1030
aS'Good'
p1031
aS'aimed'
p1032
aS'serologic'
p1033
aS'receive'
p1034
aS'collection sheets'
p1035
aS'sheets'
p1036
aS'between'
p1037
aS'posterior'
p1038
aS'cytotoxic'
p1039
aS'fifth'
p1040
aS'HBsAg following'
p1041
aS'linked'
p1042
aS'immunized'
p1043
aS'HBsAg vaccine'
p1044
aS'volunteers immunized'
p1045
aS'Drug'
p1046
aS'length'
p1047
aS'size'
p1048
aS'otorhinolaryngologist'
p1049
aS'Finlay'
p1050
aS'Finlay Hospital'
p1051
aS'J Finlay'
p1052
aS'Hospital'
p1053
aS'confirmed'
p1054
aS'adjuvant'
p1055
aS'improved'
p1056
aS'value'
p1057
aS'novel'
p1058
aS'drug'
p1059
aS'responders anti'
p1060
aS'per study'
p1061
aS'number'
p1062
aS'doses per'
p1063
aS'concentration'
p1064
aS'treatment group'
p1065
aS'Fisher'
p1066
aS'enhancement'
p1067
aS'written'
p1068
aS'based'
p1069
aS'severity'
p1070
aS'elicit'
p1071
aS'work'
p1072
aS'history'
p1073
aS'potent'
p1074
aS'showed'
p1075
aS'Nasal administration'
p1076
aS'chronic carriers'
p1077
aS'HBc seroconversion'
p1078
aS'intranasal'
p1079
aS'address'
p1080
aS'77'
p1081
aS'Th cell'
p1082
aS'nucleic acids'
p1083
aS'previously'
p1084
aS'enzyme linked'
p1085
aS'expressed'
p1086
aS'up'
p1087
aS'CIGB'
p1088
aS'study staff'
p1089
aS'licensed nasal'
p1090
aS'give'
p1091
aS'formal'
p1092
aS'fluorescent'
p1093
aS'50g'
p1094
aS'M cells'
p1095
aS'against HBsAg'
p1096
aS'fever'
p1097
aS'under'
p1098
aS'inflammatory'
p1099
aS'significant'
p1100
aS'resolving'
p1101
aS'effects'
p1102
aS'moderate'
p1103
aS'received'
p1104
aS'there'
p1105
aS'over'
p1106
aS'differences'
p1107
aS'only'
p1108
aS'were evaluated'
p1109
aS'antibodies'
p1110
aS'mucosa'
p1111
aS'reporting'
p1112
aS'significantly'
p1113
aS'Anti HBs'
p1114
aS'made'
p1115
aS'damage'
p1116
aS'ELISA'
p1117
aS'ELISA kits'
p1118
aS'kits'
p1119
aS'observation'
p1120
aS'assigned'
p1121
aS'Furthermore'
p1122
aS'HBV infected'
p1123
aS'mean'
p1124
aS'assessed'
p1125
aS'within'
p1126
aS'l per'
p1127
aS'hyper'
p1128
aS'higher'
p1129
aS'serum antibody'
p1130
aS'vaccine doses'
p1131
aS'71'
p1132
aS'mixed'
p1133
aS'testing'
p1134
aS'Nasal'
p1135
aS'Health'
p1136
aS'Organization'
p1137
aS'Health Organization'
p1138
aS'prior'
p1139
aS'25'
p1140
aS'12h 24h'
p1141
aS'24h 48h'
p1142
aS'48h 72h'
p1143
aS'48h'
p1144
aS'actively'
p1145
aS'were actively'
p1146
aS'actively recorded'
p1147
aS'via nasal'
p1148
aS'via'
p1149
aS'after each'
p1150
aS'vaccine dose'
p1151
aS'wash'
p1152
aS'pre'
p1153
aS'defined'
p1154
aS'conditions'
p1155
aS'level'
p1156
aS'NASVAC'
p1157
aS'allocated'
p1158
aS'saline solution'
p1159
aS'saline'
p1160
aS'volume'
p1161
aS'5ml'
p1162
aS'B vaccine'
p1163
aS'per nostril'
p1164
aS'nostril'
p1165
aS'available'
p1166
aS'showing'
p1167
aS'controlled'
p1168
aS'placebo controlled'
p1169
aS'male'
p1170
aS'healthy male'
p1171
aS'methods'
p1172
aS'randomly allocated'
p1173
aS'randomly'
p1174
aS'were also'
p1175
aS'similar'
p1176
aS'induction'
p1177
aS'All subjects'
p1178
aS'such'
p1179
aS'provided'
p1180
aS'component'
p1181
aS'frequent'
p1182
aS'cases'
p1183
aS'measured'
p1184
aS'medical'
p1185
aS'than 10IU'
p1186
aS'DC'
p1187
aS'male adults'
p1188
aS'test'
p1189
aS'Individuals'
p1190
aS'clearly'
p1191
aS'containing'
p1192
aS'Briefly'
p1193
aS'thank'
p1194
aS'seroprotected'
p1195
aS'incubated'
p1196
aS'physiologic'
p1197
aS'physiologic saline'
p1198
aS'comparison'
p1199
aS'consent'
p1200
aS'informed consent'
p1201
aS'informed'
p1202
aS'particle'
p1203
aS'Recent'
p1204
aS'tests'
p1205
aS'proportional'
p1206
aS'conjugate'
p1207
aS'HBc antibodies'
p1208
aS'purity'
p1209
aS'estimated'
p1210
aS'Similarly'
p1211
aS'cells'
p1212
aS'rats'
p1213
aS'Th'
p1214
aS'interaction'
p1215
aS'nucleic'
p1216
aS'neither'
p1217
aS'enzyme'
p1218
aS'Blood'
p1219
aS'CIGB Havana'
p1220
aS'particulate'
p1221
aS'permanent'
p1222
aS'bothersome'
p1223
aS'subject'
p1224
aS'Recombinant'
p1225
aS'levels'
p1226
aS'HB'
p1227
aS'Heberbiovac HB'
p1228
aS'Heberbiovac'
p1229
aS'co administration'
p1230
aS'hour'
p1231
aS'hour after'
p1232
aS'between vaccine'
p1233
aS'period'
p1234
aS'rate'
p1235
aS'HBs antibody'
p1236
aS'antibody levels'
p1237
aS'subtype'
p1238
aS'HBsAg subtype'
p1239
aS'comprising'
p1240
aS'Local'
p1241
aS'against HBcAg'
p1242
aS'Local site'
p1243
aS'site'
p1244
aS'through'
p1245
aS'100IU'
p1246
aS'acute'
p1247
aS'Only'
p1248
aS'intervals'
p1249
aS'There'
p1250
aS'There were'
p1251
aS'virus HBV'
p1252
aS'individuals'
p1253
aS'withdrew'
p1254
aS'nor'
p1255
aS'responder'
p1256
aS'adverse reactions'
p1257
aS'symptom'
p1258
aS'were defined'
p1259
aS'nasal flu'
p1260
aS'flu'
p1261
aS'HBs titers'
p1262
aS'were reported'
p1263
aS'gene'
p1264
aS'temperature'
p1265
aS'cell'
p1266
aS'following inoculation'
p1267
aS'derived'
p1268
aS'group withdrew'
p1269
aS'inoculated'
p1270
aS'needed'
p1271
aS'reaction'
p1272
aS'comprising HBV'
p1273
aS'candidate comprising'
p1274
aS'demonstration'
p1275
aS'nostril Adverse'
p1276
aS'75 All'
p1277
aS'Adverse reactions'
p1278
aS'titer 10IU'
p1279
aS'titers were'
p1280
aS'dose Anti'
p1281
aS'recorded 1h'
p1282
aS'seronegative during'
p1283
aS'were all'
p1284
aS'remained seronegative'
p1285
aS'1h 6h'
p1286
aS'evaluated using'
p1287
aS'1h'
p1288
aS'using corresponding'
p1289
aS'HBc titers'
p1290
aS'corresponding ELISA'
p1291
aS'schedule while'
p1292
aS'while'
p1293
aS'elicited anti'
p1294
aS'tolerated Adverse'
p1295
aS'all self'
p1296
aS'HBs titer'
p1297
aS'reactions included'
p1298
aS'dosages'
p1299
aS'9 physiologic'
p1300
aS'surface HBsAg'
p1301
aS'guidelines'
p1302
aS'comprising hepatitis'
p1303
aS'blinded placebo'
p1304
aS'recombinant antigens'
p1305
aS'Practice guidelines'
p1306
aS'antigens HBcAg'
p1307
aS'controlled randomized'
p1308
aS'randomized clinical'
p1309
aS'models'
p1310
aS'Participants ranged'
p1311
aS'Clinical'
p1312
aS'candidate NASVAC'
p1313
aS'ranged'
p1314
aS'Practice'
p1315
aS'Clinical Practice'
p1316
aS'guidelines Participants'
p1317
aS'markers'
p1318
aS'HBV recombinant'
p1319
aS'HBV surface'
p1320
aS'NASVAC comprising'
p1321
aS'nature'
p1322
aS'II'
p1323
aS'protective'
p1324
aS'wash samples'
p1325
aS'protective levels'
p1326
aS'dripping'
p1327
aS'anterior'
p1328
aS'samples were'
p1329
aS'adjuvants'
p1330
aS'Becton'
p1331
aS'Accuspray Becton'
p1332
aS'Dickinson'
p1333
aS'Accuspray'
p1334
aS'Becton Dickinson'
p1335
aS'predominated'
p1336
aS'conducted'
p1337
aS'effect'
p1338
aS'length HBcAg'
p1339
aS'parenteral'
p1340
aS'APCs'
p1341
aS'collected'
p1342
aS'UMELISA'
p1343
aS'reported during'
p1344
aS'assay'
p1345
aS'nasally'
p1346
aS'were given'
p1347
aS'given'
p1348
aS'HBc UMELISA'
p1349
aS'products'
p1350
aS's exact'
p1351
aS'exact'
p1352
aS'exact test'
p1353
aS'immune response'
p1354
aS'determinants'
p1355
aS'nurse'
p1356
aS'substrate'
p1357
aS'phosphatase'
p1358
aS'alkaline'
p1359
aS'alkaline phosphatase'
p1360
aS'symptoms'
p1361
aS'doses were'
p1362
aS'mean anti'
p1363
aS'irritating'
p1364
aS'known'
p1365
aS'confidence'
p1366
aS'confidence intervals'
p1367
aS'intervals were'
p1368
aS'Individuals were'
p1369
aS'acids'
p1370
aS'events included'
p1371
aS'Solicited'
p1372
aS'immunosorbent'
p1373
aS'linked immunosorbent'
p1374
aS'immunosorbent assay'
p1375
aS'symptom graded'
p1376
aS'graded'
p1377
aS'interference'
p1378
aS'frequently'
p1379
aS'more frequently'
p1380
aS'medical attention'
p1381
aS'require medical'
p1382
aS'may'
p1383
aS'require'
p1384
aS'attention'
p1385
aS'may require'
p1386
aS'reaction category'
p1387
aS'category'
p1388
aS'state'
p1389
aS'sample size'
p1390
aS'dosages of 125l'
p1391
aS'Th1 response vital'
p1392
aS'cost'
p1393
aS'vital'
p1394
aS'protein in suppressing'
p1395
aS'125l per'
p1396
aS'response vital'
p1397
aS'suppressing'
p1398
aS'125l'
p1399
aS'development of more'
p1400
aS'limited'
p1401
aS'candidate for nasal'
p1402
aS'Solicited systemic adverse'
p1403
aS'HBcAg over nasally'
p1404
aS'seroprotection rate'
p1405
aS'facilities'
p1406
aS'randomized placebo'
p1407
aS'hematology tests'
p1408
aS'annoying may require'
p1409
aS'appetite'
p1410
aS'appetite nausea vomiting'
p1411
aS'years There'
p1412
aS'five vaccine'
p1413
aS'group Sneezing'
p1414
aS'spray calcitonin'
p1415
aS'disability'
p1416
aS'height between'
p1417
aS'two participants'
p1418
aS'usual activity'
p1419
aS'Additionally'
p1420
aS'recording of local'
p1421
aS'within 72hours'
p1422
aS'collected at baseline'
p1423
aS'risk'
p1424
aS'physician'
p1425
aS'terminal'
p1426
aS'dripping nasal stuffiness'
p1427
aS'induce strong HBV'
p1428
aS'measured in saliva'
p1429
aS'ulceration and nasal'
p1430
aS'viral'
p1431
aS'immunization interval'
p1432
aS'antibody titer'
p1433
aS'frequent adverse'
p1434
aS'spray at days'
p1435
aS'high mucosal'
p1436
aS'observations at 6h'
p1437
aS'trial corresponding'
p1438
aS'estimates'
p1439
aS'children became'
p1440
aS'Quality Control CECMED'
p1441
aS'subjects having'
p1442
aS'study indicate'
p1443
aS'even'
p1444
aS'post inoculation'
p1445
aS'More than 97'
p1446
aS'HBcAg to act'
p1447
aS'abnormal baseline biochemistry'
p1448
aS'two moderate adverse'
p1449
aS'study screening'
p1450
aS'18 45 years'
p1451
aS'healthy young adults'
p1452
aS'chemical and basic'
p1453
aS'IgA'
p1454
aS'included fever'
p1455
aS'center randomized'
p1456
aS'antibodies were'
p1457
aS'behavioural changes'
p1458
aS'use Nasal'
p1459
aS'frequency of sneezing'
p1460
aS'more immunogenic'
p1461
aS'approximately 5 10'
p1462
aS'analysis Further'
p1463
aS'cutaneous rash Information'
p1464
aS'protection'
p1465
aS'enough to elicit'
p1466
aS'active'
p1467
aS'human sera Briefly'
p1468
aS'behavioral risk'
p1469
aS'formulation consisting'
p1470
aS'irritating potential acute'
p1471
aS'reports'
p1472
aS'Hospital Havana Cuba'
p1473
aS'taking into consideration'
p1474
aS'were kept under'
p1475
aS'Sera with undetectable'
p1476
aS'Recombinant HBsAg reacts'
p1477
aS'changes'
p1478
aS'antibody levels were'
p1479
aS'antibody were'
p1480
aS'explained'
p1481
aS'recipients at day'
p1482
aS'levels and 95'
p1483
aS'significantly higher'
p1484
aS'study vaccines'
p1485
aS'CTL'
p1486
aS'Individuals were excluded'
p1487
aS'moderate or severe'
p1488
aS'other nasal vaccines'
p1489
aS'specific helper'
p1490
aS'nasal itching palate'
p1491
aS'hospital'
p1492
aS'used in specific'
p1493
aS'sampling including antigen'
p1494
aS'tabulated'
p1495
aS'formulation Sterile physiologic'
p1496
aS'nasally administered drugs'
p1497
aS'125 l per'
p1498
aS'therefore'
p1499
aS'Preclinical studies'
p1500
aS'against HBV nucleocapsid'
p1501
aS'aware'
p1502
aS'98'
p1503
aS'muscle aches decreased'
p1504
aS'populations DC'
p1505
aS'Blood saliva'
p1506
aS'most commonly reported'
p1507
aS'administration also allows'
p1508
aS'97'
p1509
aS'All sera'
p1510
aS'HBeAg'
p1511
aS'race predominated'
p1512
aS'adverse event profile'
p1513
aS'anti HBV vaccine'
p1514
aS'mm'
p1515
aS'corresponding to headache'
p1516
aS'phase monoclonal'
p1517
aS'levels were expressed'
p1518
aS'seroconversion against HBcAg'
p1519
aS'6h and 12h'
p1520
aS'All aspects'
p1521
aS'9 Only'
p1522
aS'HBs titers around'
p1523
aS'indicated'
p1524
aS'HBc specific Th'
p1525
aS'were assigned'
p1526
aS'period following'
p1527
aS'persistently abnormal'
p1528
aS'commercial ultramicroanalytic'
p1529
aS'blood mononuclear cells'
p1530
aS'were classified'
p1531
aS'diseases immunosuppressive disorders'
p1532
aS'immunization Solicited'
p1533
aS'subtype CIGB Havana'
p1534
aS'competitive sequential immunoenzymatic'
p1535
aS'vital for viral'
p1536
aS'HBs anti HBc'
p1537
aS'acemannan'
p1538
aS'severe adverse'
p1539
aS'wash samples All'
p1540
aS'HBs antibody level'
p1541
aS'were monitored'
p1542
aS'block antigenic'
p1543
aS'high responders'
p1544
aS'22nm particle'
p1545
aS'dose of 50'
p1546
aS'polymerase'
p1547
aS'43 subjects signed'
p1548
aS'events were monitored'
p1549
aS'multiple comparisons Geometric'
p1550
aS'only 30 days'
p1551
aS'methods Concurrent comparison'
p1552
aS'Genbank accession number'
p1553
aS'device Accuspray'
p1554
aS'percentage anti'
p1555
aS'group with approximately'
p1556
aS'found in participants'
p1557
aS'were seronegative'
p1558
aS'usual activity frequent'
p1559
aS'seroconversion for anti'
p1560
aS'UMELISA Immunoassay'
p1561
aS'vaccine doses were'
p1562
aS'both antigens Rates'
p1563
aS'vaccines currently licensed'
p1564
aS'chronically'
p1565
aS'before'
p1566
aS'use Nasal spray'
p1567
aS'sequential'
p1568
aS'T lymphocytes CTL'
p1569
aS'randomized placebo controlled'
p1570
aS'production'
p1571
aS'nasal mucosa septum'
p1572
aS'Health Organization standard'
p1573
aS'400'
p1574
aS'methodologies for mucosal'
p1575
aS'contained 0 6ml'
p1576
aS'overcome'
p1577
aS'lymphocytes CTL level'
p1578
aS'antigenic determinants'
p1579
aS'other symptom'
p1580
aS'diseases'
p1581
aS'minimum ensured'
p1582
aS'immunoenzymatic'
p1583
aS'sequential immunoenzymatic assay'
p1584
aS'break'
p1585
aS'inoculation under'
p1586
aS'first hour'
p1587
aS'plates'
p1588
aS'immunogen'
p1589
aS'commercial anti HBV'
p1590
aS'Control'
p1591
aS'achieve protective'
p1592
aS'entire core'
p1593
aS'reasonably'
p1594
aS'classified'
p1595
aS'77 recorded adverse'
p1596
aS'existing antibody against'
p1597
aS'conjugate anti HBs'
p1598
aS'under routine use'
p1599
aS'thin cytoplasm'
p1600
aS'nasal adverse reactions'
p1601
aS'commercial anti HBs'
p1602
aS'per well coated'
p1603
aS'side'
p1604
aS'clinically apparent'
p1605
aS'periodical examinations'
p1606
aS'vaccine group reported'
p1607
aS'surface M cell'
p1608
aS'toxicology or otorhinolaryngology'
p1609
aS'nostril were given'
p1610
aS'very distressing interference'
p1611
aS'glycosylated'
p1612
aS'bleeding Solicited'
p1613
aS'device Accuspray Becton'
p1614
aS'seroprotective response'
p1615
aS'substantially'
p1616
aS'preliminary'
p1617
aS'higher than 10IU'
p1618
aS'network'
p1619
aS'prophylactic vaccines'
p1620
aS'characteristic'
p1621
aS'reported more'
p1622
aS'high responders anti'
p1623
aS'medicine'
p1624
aS'Toxicology CENATOX'
p1625
aS'vaccine antigens'
p1626
aS'screening at day'
p1627
aS'route showing'
p1628
aS'anti HBs anti'
p1629
aS'Conversely patients resolving'
p1630
aS'site adverse'
p1631
aS'monoclonal antibodies'
p1632
aS'day period following'
p1633
aS'B infection'
p1634
aS'cirrhosis'
p1635
aS'Concurrent comparison'
p1636
aS'participants prior'
p1637
aS'toxicity and local'
p1638
aS'HBc seroconversion after'
p1639
aS'detecting'
p1640
aS'were made'
p1641
aS'Sneezing palate itching'
p1642
aS'chronic diseases immunosuppressive'
p1643
aS'showed seroconversion'
p1644
aS'study after obtaining'
p1645
aS'had clinically'
p1646
aS'hematological parameters'
p1647
aS'inoculation Adverse'
p1648
aS'long term consequences'
p1649
aS'CENATOX and Carlos'
p1650
aS'doses were needed'
p1651
aS'mucosa septum'
p1652
aS'were combined'
p1653
aS'persistently abnormal baseline'
p1654
aS'sensitivity Similarly further'
p1655
aS'resolving spontaneously'
p1656
aS'signs nor behavioural'
p1657
aS'computer generated list'
p1658
aS'HBc antibody'
p1659
aS'observations'
p1660
aS'addition to self'
p1661
aS'HBsAgHBcAg'
p1662
aS'percentage'
p1663
aS'recent'
p1664
aS'Anti HBc antibody'
p1665
aS'percentages were compared'
p1666
aS'72h following'
p1667
aS'potential acute toxicity'
p1668
aS'HBsAg and 50g'
p1669
aS'there were more'
p1670
aS'other investigators'
p1671
aS'abnormalities in blood'
p1672
aS'HBs 10'
p1673
aS'vaccine using'
p1674
aS'likely'
p1675
aS'incubated with natural'
p1676
aS'sampling including'
p1677
aS'were mostly reported'
p1678
aS'plasmid'
p1679
aS'antigen presenting cells'
p1680
aS'intervals were estimated'
p1681
aS'enables'
p1682
aS'inoculation of any'
p1683
aS'modulatory'
p1684
aS'clinical situation'
p1685
aS'fashion'
p1686
aS'group Individuals'
p1687
aS'levels against HBsAg'
p1688
aS'renal dialysis patients'
p1689
aS'clinical chemistries'
p1690
aS'adverse events reported'
p1691
aS'collected and categorized'
p1692
aS'populations DC Additionally'
p1693
aS'time intervals'
p1694
aS'same time'
p1695
aS'72h after inoculation'
p1696
aS'Center Havana'
p1697
aS'Briefly UMELISA plates'
p1698
aS'infection Conversely patients'
p1699
aS'Conversely patients'
p1700
aS'nasal formulation'
p1701
aS'access Furthermore'
p1702
aS'month after'
p1703
aS'consequences of chronic'
p1704
aS'subtype obtained'
p1705
aS'Nasal spray devices'
p1706
aS'continuous'
p1707
aS'estimate each rate'
p1708
aS'immunization schedule Following'
p1709
aS'any other symptom'
p1710
aS'well known nasally'
p1711
aS'mouth'
p1712
aS'Two applications per'
p1713
aS'Nine participants'
p1714
aS'immunogenicity profile Recent'
p1715
aS'remaining determinants'
p1716
aS'experiments in mice'
p1717
aS'young adults'
p1718
aS'nucleocapsid'
p1719
aS'age weight'
p1720
aS'potential therapeutic'
p1721
aS'principle'
p1722
aS'75 seroprotection'
p1723
aS'72hours following inoculation'
p1724
aS'order to optimize'
p1725
aS'came'
p1726
aS'per well'
p1727
aS'Nasal administration also'
p1728
aS'value 0 05'
p1729
aS'chills headache'
p1730
aS'studies in mice'
p1731
aS'activity frequent'
p1732
aS'measurement of serum'
p1733
aS'events between'
p1734
aS'effects underlines'
p1735
aS'existing antibody'
p1736
aS'intranasal vaccine'
p1737
aS'devices Accuspray'
p1738
aS'5ml Participants'
p1739
aS'90 days'
p1740
aS'range 18 45'
p1741
aS'placebo study'
p1742
aS'combined prophylactic vaccines'
p1743
aS'aches decreased'
p1744
aS'Volunteers were'
p1745
aS'Preclinical mouse studies'
p1746
aS'natural HBsAg'
p1747
aS'immune compromised hosts'
p1748
aS'rabbit anti HBc'
p1749
aS'nasal adverse events'
p1750
aS'three doses were'
p1751
aS'15 minutes apart'
p1752
aS'pocket'
p1753
aS'severity mild moderate'
p1754
aS'polymerase and envelope'
p1755
aS'antibodies were measured'
p1756
aS'report'
p1757
aS'50g HBcAg'
p1758
aS'devices still need'
p1759
aS'infrequent'
p1760
aS'were instructed'
p1761
aS'microscopy'
p1762
aS'consisting'
p1763
aS'through novel'
p1764
aS'mouth Two'
p1765
aS'local damage'
p1766
aS'adverse events predominated'
p1767
aS'study products were'
p1768
aS'Nine participants received'
p1769
aS'100 showed seroconversion'
p1770
aS'experiments conducted'
p1771
aS'treatment display'
p1772
aS'peripheral'
p1773
aS'core antigen'
p1774
aS'alterations'
p1775
aS'dendritic cell'
p1776
aS'patients with self'
p1777
aS'result'
p1778
aS'access very specialized'
p1779
aS'total of two'
p1780
aS'virus HBV worldwide'
p1781
aS'blood samples were'
p1782
aS'other particulate'
p1783
aS'immunization interval protocol'
p1784
aS'500DC'
p1785
aS'frequent and annoying'
p1786
aS'applications per nostril'
p1787
aS'weak HBV'
p1788
aS'05'
p1789
aS'IU l according'
p1790
aS'also likely'
p1791
aS'core antigen gene'
p1792
aS'completion'
p1793
aS'protected'
p1794
aS'older individuals'
p1795
aS'tolerance'
p1796
aS'Clinically significant events'
p1797
aS'HBcAg molecule'
p1798
aS'were closely'
p1799
aS'glycosylated form'
p1800
aS'terms'
p1801
aS'g derived'
p1802
aS'visualization'
p1803
aS'weak'
p1804
aS'patients resolving acute'
p1805
aS'combined prophylactic'
p1806
aS'per nostril were'
p1807
aS'combined HBsAg'
p1808
aS'local and systemic'
p1809
aS'sterile conditions'
p1810
aS'cells PBMCs'
p1811
aS'medication prior inoculation'
p1812
aS'decreased appetite'
p1813
aS'adults Local'
p1814
aS'tests against'
p1815
aS'commercial recombinant'
p1816
aS'up to 71'
p1817
aS'were not involved'
p1818
aS'nasal dripping nasal'
p1819
aS'basis but adverse'
p1820
aS'made for multiple'
p1821
aS'any symptom graded'
p1822
aS'activity on co'
p1823
aS'reach 75 seroprotection'
p1824
aS'reagents 10'
p1825
aS'flu or other'
p1826
aS'revealed by EM'
p1827
aS'well tolerated safe'
p1828
aS'virus after treatment'
p1829
aS'10IU l seroprotection'
p1830
aS'height'
p1831
aS'frequently reported among'
p1832
aS'Board'
p1833
aS'Samples'
p1834
aS'international units per'
p1835
aS'inflammatory analgesics'
p1836
aS'specific post'
p1837
aS'vessel status after'
p1838
aS'fluorigenic'
p1839
aS'vaccine formulation Sterile'
p1840
aS'basis'
p1841
aS'three'
p1842
aS'5 10'
p1843
aS'severe adverse event'
p1844
aS'acids bound'
p1845
aS'formulation and devices'
p1846
aS'same typical'
p1847
aS'type of cytokine'
p1848
aS'life'
p1849
aS'hospitalization'
p1850
aS'efficacy'
p1851
aS'drugs'
p1852
aS'participants were seronegative'
p1853
aS'adverse effects'
p1854
aS'nasal drug'
p1855
aS'hepatitis B infection'
p1856
aS'exception'
p1857
aS'acceptable local adverse'
p1858
aS'Recombinant HBsAg'
p1859
aS'seroprotection with respect'
p1860
aS'events predominated over'
p1861
aS'titers against'
p1862
aS'spontaneously'
p1863
aS'cause interference'
p1864
aS'other reactions'
p1865
aS'years of age'
p1866
aS'procedure'
p1867
aS'life threatening'
p1868
aS'HBcAg as vaccine'
p1869
aS'Sterile physiologic'
p1870
aS'e g acemannan'
p1871
aS'Among'
p1872
aS'subjects were classified'
p1873
aS'impact of HBcAg'
p1874
aS'characterize'
p1875
aS'category and all'
p1876
aS'kind of vaccine'
p1877
aS'vaccine candidate were'
p1878
aS'Nasal spray'
p1879
aS'mouse'
p1880
aS'l low responders'
p1881
aS'immunogenicity studies'
p1882
aS'reported more frequently'
p1883
aS'resolving acute hepatitis'
p1884
aS'cellular responses'
p1885
aS'reports came'
p1886
aS'HBs alkaline'
p1887
aS'also no clinically'
p1888
aS'adults between'
p1889
aS'response in mice'
p1890
aS'serum clinical chemistry'
p1891
aS'vaccine candidate showed'
p1892
aS'day 30 one'
p1893
aS'independent'
p1894
aS'Genbank accession'
p1895
aS'double blinded study'
p1896
aS'formal hypothesis'
p1897
aS'possible'
p1898
aS'60 days All'
p1899
aS'nucleocapsid polymerase'
p1900
aS'co administered'
p1901
aS'All study products'
p1902
aS'antibodies in human'
p1903
aS'Solicited adverse'
p1904
aS'compared'
p1905
aS'adults between 18'
p1906
aS'kept'
p1907
aS'scenario'
p1908
aS'l All'
p1909
aS'HBV worldwide'
p1910
aS'aqueous and transparent'
p1911
aS'contact'
p1912
aS'otorhinolaryngologist examination'
p1913
aS'were more than'
p1914
aS'phase monoclonal antibodies'
p1915
aS'efficacy of antiviral'
p1916
aS'diarrhea'
p1917
aS'days and 90'
p1918
aS'biochemistry or hematology'
p1919
aS'inversely'
p1920
aS'0 73'
p1921
aS'protocol'
p1922
aS'active immunotherapy'
p1923
aS'third vaccine'
p1924
aS'Serious'
p1925
aS'l according'
p1926
aS'same time intervals'
p1927
aS'l Although anti'
p1928
aS'HBs antibodies were'
p1929
aS'cell populations'
p1930
aS'Genbank'
p1931
aS'ability of HBcAg'
p1932
aS'10 l based'
p1933
aS'2 6 13'
p1934
aS'previous'
p1935
aS'professional antigen presenting'
p1936
aS'HBs 100IU'
p1937
aS'antigens NASVAC'
p1938
aS'impaired T cell'
p1939
aS'devices still'
p1940
aS'0 9 sterile'
p1941
aS'other licensed'
p1942
aS'transformed'
p1943
aS'access very'
p1944
aS'evidenced'
p1945
aS'any general'
p1946
aS'drug behavioral'
p1947
aS'8 general malaise'
p1948
aS'advances'
p1949
aS'Clinically significant'
p1950
aS'weight and height'
p1951
aS'neither clinical adverse'
p1952
aS'screening reasons'
p1953
aS'Induction of immunity'
p1954
aS'expiration through'
p1955
aS'C terminal'
p1956
aS'considered hyper responders'
p1957
aS'All study'
p1958
aS'borosilicate 2R'
p1959
aS'apart'
p1960
aS'volunteers were'
p1961
aS'59'
p1962
aS'dosages of 125'
p1963
aS'Also'
p1964
aS'were registered'
p1965
aS'comparability'
p1966
aS'informative'
p1967
aS'immunosuppressive'
p1968
aS'rats revealed'
p1969
aS'measured by commercial'
p1970
aS'titers against HBsAg'
p1971
aS'improved in terms'
p1972
aS'nasal administration'
p1973
aS'buffer without any'
p1974
aS'million carriers'
p1975
aS'responses in mice'
p1976
aS'had abnormalities'
p1977
aS'blood vessel status'
p1978
aS'antibodies No volunteers'
p1979
aS'fifth vaccine'
p1980
aS'single otorhinolaryngologist'
p1981
aS'HBsAg subtype obtained'
p1982
aS'were excluded'
p1983
aS'received either'
p1984
aS'2 whereas systemic'
p1985
aS'antigen gene under'
p1986
aS'Solicited systemic'
p1987
aS'HBsAg and antibody'
p1988
aS'comments'
p1989
aS'seroprotection percentage'
p1990
aS'acknowledge Enrique Iglesias'
p1991
aS'participants were randomized'
p1992
aS'reasons for screen'
p1993
aS'nasal vaccines'
p1994
aS'HBV nucleocapsid'
p1995
aS'recorded by study'
p1996
aS'race predominated during'
p1997
aS'responders to licensed'
p1998
aS'vaccines plant'
p1999
aS'seroprotection over'
p2000
aS'Further'
p2001
aS'highest frequency'
p2002
aS'healthy male adult'
p2003
aS's visits'
p2004
aS'study were similar'
p2005
aS'presence of nucleic'
p2006
aS'activator enabling'
p2007
aS'need for development'
p2008
aS'months'
p2009
aS'nasal dripping'
p2010
aS'system Adverse events'
p2011
aS'staff or volunteers'
p2012
aS'reported by other'
p2013
aS'anti HBs antibodies'
p2014
aS'common scenario'
p2015
aS'nine participants'
p2016
aS'All anti'
p2017
aS'administration comprising HBsAg'
p2018
aS'under sterile conditions'
p2019
aS'nor induced local'
p2020
aS'blood samples'
p2021
aS'dialysis patients'
p2022
aS'placebo study staff'
p2023
aS'received study drug'
p2024
aS'P rez'
p2025
aS'nasal HBsAg HBcAg'
p2026
aS'internal medicine'
p2027
aS'following administration'
p2028
aS'also allows'
p2029
aS'seroconversion against'
p2030
aS'drug behavioral risk'
p2031
aS'support'
p2032
aS'W3110'
p2033
aS'HBc specific'
p2034
aS'vaccines administered through'
p2035
aS'predominated during'
p2036
aS'subjects received'
p2037
aS'posterior nasal'
p2038
aS'ultramicroanalytic enzyme'
p2039
aS'HBsAg and 50'
p2040
aS'head'
p2041
aS'antibody levels against'
p2042
aS'form'
p2043
aS'particulate nature'
p2044
aS'developed NASVAC'
p2045
aS'failure'
p2046
aS'0038 All reactions'
p2047
aS'trained physician specializing'
p2048
aS'recorded adverse'
p2049
aS'true'
p2050
aS'intervals were used'
p2051
aS'absent'
p2052
aS'formal sample size'
p2053
aS'axillary temperature 38'
p2054
aS'antigen presenting'
p2055
aS'sterile saline'
p2056
aS'group reported'
p2057
aS'until'
p2058
aS'phosphate'
p2059
aS'required intervention'
p2060
aS'Serious adverse events'
p2061
aS'between vaccine formulation'
p2062
aS'medication'
p2063
aS'Depending'
p2064
aS'presenting cells'
p2065
aS'within 72h after'
p2066
aS'substantially different than'
p2067
aS'Organization there were'
p2068
aS'principle of neutralization'
p2069
aS'vaccine candidate containing'
p2070
aS'total anti'
p2071
aS'limiting resolving'
p2072
aS'HBV vaccine such'
p2073
aS'dual behavior'
p2074
aS'single center'
p2075
aS'cirrhosis liver failure'
p2076
aS'Only two'
p2077
aS'any clinical data'
p2078
aS'comparisons Geometric mean'
p2079
aS'HBc antibodies 17'
p2080
aS'septum and mucosal'
p2081
aS'multiple comparisons'
p2082
aS'adverse signs nor'
p2083
aS'immunogenic hepatitis'
p2084
aS'HBs alkaline phosphatase'
p2085
aS'medication prior'
p2086
aS'profile Recent'
p2087
aS'system Adverse'
p2088
aS'Similarly further'
p2089
aS'10IU l low'
p2090
aS'effect of systemic'
p2091
aS'disappeared within'
p2092
aS'events were more'
p2093
aS'vaccines administered'
p2094
aS'Health Organization there'
p2095
aS'toxicological'
p2096
aS'period following administration'
p2097
aS'inability to contact'
p2098
aS'self reporting'
p2099
aS'damage In addition'
p2100
aS'administration of HBV'
p2101
aS'fact'
p2102
aS'single nasal vaccine'
p2103
aS'basic hematology'
p2104
aS'patients include'
p2105
aS'adult'
p2106
aS'recombinant HBcAg Biokit'
p2107
aS'Anti HBc UMELISA'
p2108
aS'detecting at least'
p2109
aS'activated'
p2110
aS'volunteer received'
p2111
aS'after each immunization'
p2112
aS'cirrhosis liver'
p2113
aS'Information on any'
p2114
aS'HBV chronically infected'
p2115
aS'ELISA adapted'
p2116
aS'disorders'
p2117
aS'mechanisms for antigen'
p2118
aS'institution Five'
p2119
aS'seroprotection rate increased'
p2120
aS'spray calcitonin salmon'
p2121
aS'defined as axillary'
p2122
aS'adjuvants gene'
p2123
aS'Two applications'
p2124
aS'functioning may require'
p2125
aS'response to HBsAg'
p2126
aS'solution Although there'
p2127
aS'small volumes'
p2128
aS'similar surveillance'
p2129
aS'virus treatment'
p2130
aS'NASVAC or placebo'
p2131
aS'event rate exceeded'
p2132
aS'doses 85'
p2133
aS'units per'
p2134
aS'used Genbank'
p2135
aS'mean antibody titer'
p2136
aS'well documented state'
p2137
aS'Volunteers'
p2138
aS'anti HBc UMELISA'
p2139
aS'chronic infection Conversely'
p2140
aS'prophylactic'
p2141
aS'antibody against hepatitis'
p2142
aS'cell activator enabling'
p2143
aS'applications per'
p2144
aS'received study'
p2145
aS'derived recombinant'
p2146
aS'reported previously'
p2147
aS'antibodies from serum'
p2148
aS'single center randomized'
p2149
aS'0 No abnormalities'
p2150
aS'absent mild'
p2151
aS'luminal surface through'
p2152
aS'prevent'
p2153
aS'bleeding Solicited systemic'
p2154
aS'48hours'
p2155
aS'intranasal vaccine candidate'
p2156
aS'T cell responses'
p2157
aS'undertaken to determine'
p2158
aS'tests against HBsAg'
p2159
aS'demonstrated seroconversion'
p2160
aS'qualitative detection'
p2161
aS'solution All'
p2162
aS'rash Information'
p2163
aS'seroprotected subjects'
p2164
aS'phosphate buffer'
p2165
aS'blood products'
p2166
aS'nasal administration comprising'
p2167
aS'adult volunteers Written'
p2168
aS'assistance'
p2169
aS'under sterile'
p2170
aS'HBc quantification'
p2171
aS'variables Adverse events'
p2172
aS'very specialized'
p2173
aS'acute toxicity'
p2174
aS'vaccine Furthermore'
p2175
aS'boost'
p2176
aS'than 400 million'
p2177
aS'filled'
p2178
aS'liter IU'
p2179
aS'were administered'
p2180
aS'statistically'
p2181
aS'any adverse'
p2182
aS'HBcAg combined'
p2183
aS'ulceration'
p2184
aS'vaccine candidate developed'
p2185
aS'Havana Cuba All'
p2186
aS'mononuclear cells'
p2187
aS'Each vial'
p2188
aS'groups'
p2189
aS'HBs UMELISA'
p2190
aS'along'
p2191
aS'disappeared'
p2192
aS'HBsAg Recombinant HBsAg'
p2193
aS'immunization further benefit'
p2194
aS'informed consent Individuals'
p2195
aS'Research Ethics Board'
p2196
aS'novel adjuvants'
p2197
aS'significant events'
p2198
aS'development of mucosal'
p2199
aS'events included fever'
p2200
aS'reagents'
p2201
aS'differences between'
p2202
aS'recipients 0 0038'
p2203
aS'administered drugs'
p2204
aS'permanent impairment'
p2205
aS'B virus anti'
p2206
aS'sneezing nasal'
p2207
aS'were found'
p2208
aS'nor behavioural'
p2209
aS'bulbs'
p2210
aS'vaccine using similar'
p2211
aS'remaining determinants After'
p2212
aS'sterile phosphate'
p2213
aS'vaccines vaccines'
p2214
aS'lymphocytes CTL'
p2215
aS'visit'
p2216
aS'optimize'
p2217
aS'mucosal nasal'
p2218
aS'least one'
p2219
aS'scenario in patients'
p2220
aS'HBV core'
p2221
aS'hospital for 48hours'
p2222
aS'response in up'
p2223
aS'normal functioning'
p2224
aS'purified from strain'
p2225
aS'organized'
p2226
aS'acceptable'
p2227
aS'apparent'
p2228
aS'envelope'
p2229
aS'were undertaken'
p2230
aS'Recent developments'
p2231
aS'Subjects were healthy'
p2232
aS'participants as minimum'
p2233
aS'400 million'
p2234
aS'Binomial distribution point'
p2235
aS'recombinant Heberbiovac'
p2236
aS'list of random'
p2237
aS'hospitalizations were'
p2238
aS'borosilicate'
p2239
aS'were negative'
p2240
aS'polyclonal and multi'
p2241
aS'28nm as characterized'
p2242
aS'actively and always'
p2243
aS'cell pockets'
p2244
aS'labeled'
p2245
aS'obtained from serum'
p2246
aS'assay anti HBs'
p2247
aS'contact after'
p2248
aS'all other'
p2249
aS'septum'
p2250
aS'Each vial contained'
p2251
aS'g acemannan'
p2252
aS'were assigned arbitrarily'
p2253
aS'18 and 45'
p2254
aS'sera Briefly'
p2255
aS'T cell immunity'
p2256
aS'tilted backwards'
p2257
aS'detect differences'
p2258
aS'group withdrew voluntarily'
p2259
aS'allowed'
p2260
aS'72h after'
p2261
aS'Induction'
p2262
aS'containing recombinant'
p2263
aS'cells M cells'
p2264
aS'CECMED in Cuba'
p2265
aS'dialysis'
p2266
aS'remaining 19 participants'
p2267
aS'immunity Nasal administration'
p2268
aS'chemical'
p2269
aS'level in patients'
p2270
aS'criterion'
p2271
aS'stored in borosilicate'
p2272
aS'terms of sensitivity'
p2273
aS'further benefit'
p2274
aS'contribute'
p2275
aS'immunomodulation on HBsAg'
p2276
aS'spray device'
p2277
aS'strong mucosal'
p2278
aS'500DC mm'
p2279
aS'applications'
p2280
aS'graded as moderate'
p2281
aS'work efficiently'
p2282
aS'performed periodical'
p2283
aS'designed'
p2284
aS'reactions were self'
p2285
aS'placebo delivered'
p2286
aS'vaccine Heberbiovac HB'
p2287
aS'natural'
p2288
aS'liquid'
p2289
aS'persistent or permanent'
p2290
aS'tryptophan promoter'
p2291
aS'vaccine candidate tested'
p2292
aS'second vaccine doses'
p2293
aS'standard parenteral HBV'
p2294
aS'form HBcAg'
p2295
aS'were healthy male'
p2296
aS'immunogen even without'
p2297
aS'ultramicroanalytic'
p2298
aS'HBs equal'
p2299
aS'typical'
p2300
aS'site adverse events'
p2301
aS'72h following inoculation'
p2302
aS'expressed and purified'
p2303
aS'number X02763'
p2304
aS'appetite nausea'
p2305
aS'products were'
p2306
aS'400 million carriers'
p2307
aS'statistical'
p2308
aS'one adverse'
p2309
aS'still'
p2310
aS'microscopy EM'
p2311
aS'monitor'
p2312
aS'local tolerance All'
p2313
aS'proportion hypo'
p2314
aS'adverse event rate'
p2315
aS'B virus treatment'
p2316
aS'useful to overcome'
p2317
aS'HBV chronic infection'
p2318
aS'included persistently'
p2319
aS'nasal vaccine Furthermore'
p2320
aS'nose or digestive'
p2321
aS'uptake'
p2322
aS'serum antibody response'
p2323
aS'than 400'
p2324
aS'resulted in recent'
p2325
aS'phase antigen'
p2326
aS'protein expressed'
p2327
aS'titers around'
p2328
aS'obtaining'
p2329
aS'bound'
p2330
aS'congestion sneezing'
p2331
aS'were eligible'
p2332
aS'limited HBV'
p2333
aS'acknowledge Enrique'
p2334
aS'HBcAg particles'
p2335
aS'Dawley rats'
p2336
aS'HBcAg Biokit Barcelona'
p2337
aS'conjugate anti'
p2338
aS'term'
p2339
aS'UMELISA Immunoassay Center'
p2340
aS'immunoglobulin within'
p2341
aS'proteins'
p2342
aS'total of 43'
p2343
aS'vaccine only'
p2344
aS'85'
p2345
aS'control group'
p2346
aS'study screening reasons'
p2347
aS'following inoculation Adverse'
p2348
aS'abnormal'
p2349
aS'achieve protective anti'
p2350
aS'balanced'
p2351
aS'sponsor'
p2352
aS'year'
p2353
aS'recombinant HBsAg'
p2354
aS'anti HBc quantification'
p2355
aS'induced local'
p2356
aS'Solid phase'
p2357
aS'limited HBV infection'
p2358
aS'borosilicate 2R bulbs'
p2359
aS'continuous variables'
p2360
aS'doses were administered'
p2361
aS'sneezing nasal itching'
p2362
aS'responses against HBV'
p2363
aS'contained'
p2364
aS'according to otorhinolaryngologist'
p2365
aS'8IU'
p2366
aS'vaccine candidate administered'
p2367
aS'helpful comments'
p2368
aS'virus anti'
p2369
aS'format using'
p2370
aS'sense although three'
p2371
aS'excluded from enrollment'
p2372
aS'million'
p2373
aS'year 2000 Among'
p2374
aS'possibility'
p2375
aS'block antigenic determinants'
p2376
aS'secreted'
p2377
aS'first vaccine'
p2378
aS'reacting with remaining'
p2379
aS'generating more than'
p2380
aS'Enrique Iglesias'
p2381
aS'against both'
p2382
aS'virus control'
p2383
aS'allowed expiration through'
p2384
aS'Participants allocated'
p2385
aS'still need'
p2386
aS'also thank'
p2387
aS'routes'
p2388
aS'therapeutic use'
p2389
aS'itching palate itching'
p2390
aS'event in both'
p2391
aS'B cells'
p2392
aS'Sprague'
p2393
aS'symptoms very'
p2394
aS'variables'
p2395
aS'antibody were assigned'
p2396
aS'subjects showing'
p2397
aS'HBc alkaline phosphatase'
p2398
aS'defined as events'
p2399
aS'trial phase'
p2400
aS'Rates'
p2401
aS'periodical'
p2402
aS'comprises'
p2403
aS'100 showed'
p2404
aS'5 More than'
p2405
aS'one adverse event'
p2406
aS'transient nasal conditions'
p2407
aS'group included'
p2408
aS'vaccine or placebo'
p2409
aS'nasal itching'
p2410
aS'nasal spray calcitonin'
p2411
aS'impairment or damage'
p2412
aS'indicate'
p2413
aS'candidate containing recombinant'
p2414
aS'recognize any'
p2415
aS'white'
p2416
aS'cell populations DC'
p2417
aS'systemic immunity Nasal'
p2418
aS'Sneezing'
p2419
aS'mostly'
p2420
aS'II clinical studies'
p2421
aS'either NASVAC'
p2422
aS'immunomodulation'
p2423
aS'even without'
p2424
aS'study personnel before'
p2425
aS'alone or mixed'
p2426
aS'HBcAg CIGB'
p2427
aS'control Recombinant'
p2428
aS'clinical adverse signs'
p2429
aS'9 8 general'
p2430
aS'control Recombinant HBcAg'
p2431
aS'seroconversion after immunization'
p2432
aS'any study'
p2433
aS'13'
p2434
aS'effective'
p2435
aS'17'
p2436
aS'expressed as international'
p2437
aS'Five doses'
p2438
aS'institution Five doses'
p2439
aS'medical consultations'
p2440
aS'typical sandwich'
p2441
aS'within 72h'
p2442
aS'outcome'
p2443
aS'other symptom graded'
p2444
aS'addition of HBcAg'
p2445
aS'under observation'
p2446
aS'HBs or anti'
p2447
aS'other mucosal adjuvant'
p2448
aS'pre existing antibody'
p2449
aS'HBsAg reacts'
p2450
aS'rate percentages were'
p2451
aS'peptide vaccine'
p2452
aS'underlines'
p2453
aS'90 of children'
p2454
aS'up to 20'
p2455
aS'sensitivity Similarly'
p2456
aS'immunogen even'
p2457
aS'30 to get'
p2458
aS'instructed'
p2459
aS'19 participants'
p2460
aS'performance'
p2461
aS'impairment'
p2462
aS'l low'
p2463
aS'analysis Further antigenicity'
p2464
aS'HBV infected patients'
p2465
aS'multiple'
p2466
aS'trace'
p2467
aS'specific Th'
p2468
aS'Biotechnology in Havana'
p2469
aS'50g HBsAg'
p2470
aS'gene under'
p2471
aS'molecule'
p2472
aS'0 5ml Participants'
p2473
aS'study 100'
p2474
aS'positive or negative'
p2475
aS'detect'
p2476
aS'significantly increases'
p2477
aS'previous findings'
p2478
aS'Th1 type'
p2479
aS'characteristic of HBV'
p2480
aS'cellular responses against'
p2481
aS'adverse signs'
p2482
aS'participant s head'
p2483
aS'Becton Dickinson Depending'
p2484
aS'determinants After'
p2485
aS'renal'
p2486
aS'without any adjuvant'
p2487
aS'majority of infected'
p2488
aS'professional'
p2489
aS'were expressed'
p2490
aS'estimated by treatment'
p2491
aS'rate percentages'
p2492
aS'substantially different'
p2493
aS'virus as well'
p2494
aS'severity Binomial distribution'
p2495
aS'accession'
p2496
aS'parenteral administered HBsAg'
p2497
aS'tryptophan'
p2498
aS'HBsAg titer'
p2499
aS'events 58'
p2500
aS'ratio'
p2501
aS'All blood'
p2502
aS'male adult volunteers'
p2503
aS'study group included'
p2504
aS'potential acute'
p2505
aS'otorhinolaryngology'
p2506
aS'Concurrent'
p2507
aS'Binomial'
p2508
aS'Severe reactions were'
p2509
aS'HBs protective levels'
p2510
aS'previously for other'
p2511
aS'showed protective levels'
p2512
aS'More than'
p2513
aS'get'
p2514
aS'history of hepatitis'
p2515
aS'reported among'
p2516
aS'mixed with other'
p2517
aS'candidate demonstrated'
p2518
aS'ultramicroanalytic enzyme linked'
p2519
aS'S protein expressed'
p2520
aS'13 excess'
p2521
aS'secondary'
p2522
aS'same typical sandwich'
p2523
aS'regarding'
p2524
aS'vaccine Furthermore participants'
p2525
aS'age of participants'
p2526
aS'axillary temperature 39'
p2527
aS'symptom bothersome'
p2528
aS'physicians or volunteers'
p2529
aS'infection resolving'
p2530
aS'M cells transport'
p2531
aS'were used'
p2532
aS'true adverse event'
p2533
aS'audited'
p2534
aS'frequency of local'
p2535
aS'HBV core HBc'
p2536
aS'HBV nucleocapsid polymerase'
p2537
aS'adapted to small'
p2538
aS'sterile aqueous'
p2539
aS'cell immune response'
p2540
aS'per liter IU'
p2541
aS'2IU'
p2542
aS'licensed HBV'
p2543
aS'Hospital Havana'
p2544
aS'Organization standard'
p2545
aS'itching rhinorrhea nasal'
p2546
aS'investigators with licensed'
p2547
aS'study one subject'
p2548
aS'one month'
p2549
aS'blood screening regarding'
p2550
aS'candidate were'
p2551
aS'seronegative for anti'
p2552
aS'diarrhea and cutaneous'
p2553
aS'total of 77'
p2554
aS'mostly reported'
p2555
aS'1 hour'
p2556
aS'subjects were considered'
p2557
aS'similar surveillance methods'
p2558
aS'therapies'
p2559
aS'schedule Following administration'
p2560
aS'moderate adverse events'
p2561
aS'healthy adults Local'
p2562
aS'fluorescent signal'
p2563
aS'B vaccine candidate'
p2564
aS'personnel before'
p2565
aS'screen'
p2566
aS'g acemannan Whether'
p2567
aS'induced serum antibody'
p2568
aS'gratefully'
p2569
aS'chemistries and hematology'
p2570
aS'steroid'
p2571
aS'Each'
p2572
aS'also contribute'
p2573
aS'both reports came'
p2574
aS'HBsAg Recombinant'
p2575
aS'vaccine and one'
p2576
aS'purified recombinant'
p2577
aS'very specialized mechanisms'
p2578
aS'Sterile'
p2579
aS'vaccine were given'
p2580
aS'analgesics'
p2581
aS'residence'
p2582
aS'events did'
p2583
aS'more frequently reported'
p2584
aS'enabling'
p2585
aS'Chronic'
p2586
aS'participants were instructed'
p2587
aS'predominated over'
p2588
aS'induce strong'
p2589
aS'nor behavioural changes'
p2590
aS'vaccine recipients achieved'
p2591
aS'further studies'
p2592
aS'preclinical studies'
p2593
aS'Iglesias'
p2594
aS'immunity in chronic'
p2595
aS'were compared'
p2596
aS'77 adverse'
p2597
aS'studies were conducted'
p2598
aS'stored'
p2599
aS'them were'
p2600
aS'Recent advances'
p2601
aS'sampling'
p2602
aS'itching rhinorrhea'
p2603
aS'undetectable anti'
p2604
aS'most frequent adverse'
p2605
aS'considering'
p2606
aS'anosmia'
p2607
aS'achieved by nasal'
p2608
aS'Research'
p2609
aS'purified with recombinant'
p2610
aS'tonsils'
p2611
aS'registered Only'
p2612
aS'HBsAg and 100'
p2613
aS'antiviral immunogenicity'
p2614
aS'stuffiness and epistaxis'
p2615
aS'Clinically'
p2616
aS'immunopotentiating activity'
p2617
aS'sponsor institution'
p2618
aS'Subjects were'
p2619
aS'over systemic reactions'
p2620
aS'anti HBs 10'
p2621
aS'parenteral HBV'
p2622
aS'careful'
p2623
aS'73 provided'
p2624
aS'apparent abnormalities visualized'
p2625
aS'Biokit Barcelona Spain'
p2626
aS'plant derived vaccines'
p2627
aS'nasal flu vaccine'
p2628
aS'distressing'
p2629
aS'efficiently'
p2630
aS'T lymphocytes'
p2631
aS'buffer without'
p2632
aS'Spain'
p2633
aS'regarding chemical'
p2634
aS'vaccine doses Local'
p2635
aS'frequently in participants'
p2636
aS'region'
p2637
aS'clinically apparent abnormalities'
p2638
aS'used to estimate'
p2639
aS'HBc alkaline'
p2640
aS'within 72hours following'
p2641
aS'Iglesias P rez'
p2642
aS'compared by Fisher'
p2643
aS'them'
p2644
aS'equal'
p2645
aS'strain'
p2646
aS'good'
p2647
aS'inversely proportional'
p2648
aS'patients and carriers'
p2649
aS'were stored'
p2650
aS'long term'
p2651
aS'alterations or transient'
p2652
aS'diluted in sterile'
p2653
aS'helpful comments Finally'
p2654
aS'congestion sneezing nasal'
p2655
aS'encouraging taking'
p2656
aS'different'
p2657
aS'participant'
p2658
aS'through novel routes'
p2659
aS'spray device Accuspray'
p2660
aS'doctor'
p2661
aS'formulations'
p2662
aS'All but two'
p2663
aS'electron microscopy EM'
p2664
aS'surveillance'
p2665
aS'induction of immunity'
p2666
aS'further immunogenicity studies'
p2667
aS'full length recombinant'
p2668
aS'status'
p2669
aS'internal medicine toxicology'
p2670
aS'commonly reported'
p2671
aS'levels were'
p2672
aS'particulate antigens'
p2673
aS'0 0038 All'
p2674
aS'IU'
p2675
aS'formulation Phase II'
p2676
aS'Barcelona'
p2677
aS'route showing induction'
p2678
aS'sample size nine'
p2679
aS'l in order'
p2680
aS'seroprotected subjects were'
p2681
aS'total serum antibody'
p2682
aS'self limiting resolving'
p2683
aS'evaluated in duplicate'
p2684
aS'very encouraging'
p2685
aS'eligible'
p2686
aS'defined as absent'
p2687
aS'chronic patients include'
p2688
aS'became chronic carriers'
p2689
aS'steroid anti inflammatory'
p2690
aS'baseline 30'
p2691
aS'studies with HBsAg'
p2692
aS'other commercial'
p2693
aS'were more frequently'
p2694
aS'findings in experiments'
p2695
aS'cell immunity'
p2696
aS'inability'
p2697
aS'placebo group 59'
p2698
aS'g nasal flu'
p2699
aS'persistently'
p2700
aS'reporting adverse events'
p2701
aS'sprayed'
p2702
aS'Only anti HBs'
p2703
aS'levels against'
p2704
aS'among'
p2705
aS'adjustments'
p2706
aS'local or systemic'
p2707
aS'cytotoxic T cell'
p2708
aS'showed protective'
p2709
aS'Solicited adverse events'
p2710
aS'all participants were'
p2711
aS'behavioural'
p2712
aS'72hours following'
p2713
aS'comparisons Geometric'
p2714
aS'infrequent Adverse events'
p2715
aS'rats revealed neither'
p2716
aS'strong mucosal immunogenicity'
p2717
aS'patients include combined'
p2718
aS'placebo All study'
p2719
aS'immunogenicity of nasal'
p2720
aS'such samples'
p2721
aS'90 day period'
p2722
aS'Ethics'
p2723
aS'antigenicity studies'
p2724
aS'aspects'
p2725
aS'around'
p2726
aS'blinded fashion'
p2727
aS'mucosal alterations'
p2728
aS'were monitored over'
p2729
aS'recipient'
p2730
aS'90 applied doses'
p2731
aS'infected patient'
p2732
aS'were estimated pre'
p2733
aS'aqueous'
p2734
aS'irritating nor induced'
p2735
aS'corroborates previous'
p2736
aS'failures included'
p2737
aS'45 years There'
p2738
aS'envelope proteins'
p2739
aS'benefit'
p2740
aS'Subjects'
p2741
aS'either'
p2742
aS'hematology values'
p2743
aS'side effects'
p2744
aS'reported by 15'
p2745
aS'64'
p2746
aS'voluntarily'
p2747
aS'partial efficacy'
p2748
aS'recognize'
p2749
aS'candidate whereas systemic'
p2750
aS'50 g derived'
p2751
aS'than 97'
p2752
aS'than 95'
p2753
aS'influenza nasal flu'
p2754
aS'assay ELISA adapted'
p2755
aS'immunization with HBsAg'
p2756
aS'ability'
p2757
aS'HBcAg considering'
p2758
aS'HBsAg alone'
p2759
aS'doses Local'
p2760
aS'response to major'
p2761
aS'dependent and independent'
p2762
aS'specializing'
p2763
aS'allocation All'
p2764
aS'palate itching anosmia'
p2765
aS'cytotoxic T lymphocytes'
p2766
aS'chronic HBV infection'
p2767
aS'visits'
p2768
aS'7 years range'
p2769
aS'solid phase monoclonal'
p2770
aS'50 g purified'
p2771
aS'PBMCs from patients'
p2772
aS'nasal vaccine formulation'
p2773
aS'fifth dose'
p2774
aS'25 showed'
p2775
aS'categorized by body'
p2776
aS'cost and side'
p2777
aS'post immunization sera'
p2778
aS'apart All subjects'
p2779
aS'mice reconstituted'
p2780
aS'pockets'
p2781
aS'act'
p2782
aS'local tolerance'
p2783
aS'code labeled'
p2784
aS'Information'
p2785
aS'other mucosal'
p2786
aS'prolonged hospitalization'
p2787
aS'study and control'
p2788
aS'without any'
p2789
aS'major HBV'
p2790
aS'terminal region'
p2791
aS'trial were'
p2792
aS'HBsAg 10IU'
p2793
aS'immunogenicity Preclinical'
p2794
aS'determine'
p2795
aS'immunization further'
p2796
aS'intervention'
p2797
aS'proportion hypo responders'
p2798
aS'conflict of interest'
p2799
aS'g derived recombinant'
p2800
aS'g influenza nasal'
p2801
aS'than 95 purity'
p2802
aS'underwent pre study'
p2803
aS'enhancement observed'
p2804
aS'low'
p2805
aS'days All sera'
p2806
aS'secretion'
p2807
aS'needed to reach'
p2808
aS'30 Thirty'
p2809
aS'were self limiting'
p2810
aS'also allows interaction'
p2811
aS'professional antigen'
p2812
aS'Individuals were eligible'
p2813
aS'hyper responders'
p2814
aS'l One recipient'
p2815
aS'HBs anti'
p2816
aS'human clinical'
p2817
aS'physician specializing'
p2818
aS'antigenicity studies were'
p2819
aS'first report'
p2820
aS'combined formulations'
p2821
aS'Sprague Dawley'
p2822
aS'antigen gene'
p2823
aS'temperature 38'
p2824
aS'labeled matched pre'
p2825
aS'surface and core'
p2826
aS'side effects underlines'
p2827
aS'were conducted'
p2828
aS'dose however five'
p2829
aS'dose schedule formulation'
p2830
aS'inoculation Blood'
p2831
aS'wash samples were'
p2832
aS'interval'
p2833
aS'USA'
p2834
aS'l Sera'
p2835
aS'measurement'
p2836
aS'reporting adverse'
p2837
aS'blood mononuclear'
p2838
aS'enable'
p2839
aS'Th1 response'
p2840
aS'point estimates'
p2841
aS'size of 28nm'
p2842
aS'nasally administered'
p2843
aS'recombinant full'
p2844
aS'biochemistry'
p2845
aS'2000'
p2846
aS'underwent pre'
p2847
aS'efficiently as primary'
p2848
aS'comments Finally'
p2849
aS'pre incubated'
p2850
aS'More'
p2851
aS'presenting'
p2852
aS'requested'
p2853
aS'antibody titers'
p2854
aS'Preclinical toxicological studies'
p2855
aS'otorhinolaryngology Neither'
p2856
aS'more than 95'
p2857
aS'potent immunogen'
p2858
aS'post inoculation adverse'
p2859
aS'specializing in internal'
p2860
aS'each nostril'
p2861
aS'vaccine candidate demonstrated'
p2862
aS'irritating nor'
p2863
aS'any general reaction'
p2864
aS'documented state'
p2865
aS'liquid Each'
p2866
aS'event profile under'
p2867
aS'Briefly UMELISA'
p2868
aS'mixed with 50'
p2869
aS'were recruited'
p2870
aS'immunoglobulin'
p2871
aS'placebo All'
p2872
aS'behavioral'
p2873
aS'other developed'
p2874
aS'per liter'
p2875
aS'influenza'
p2876
aS'estimated pre'
p2877
aS'consider'
p2878
aS'more immunogenic hepatitis'
p2879
aS'caused'
p2880
aS'withdrew voluntarily'
p2881
aS'month'
p2882
aS'vaccines currently'
p2883
aS'25 showed protective'
p2884
aS'first and second'
p2885
aS'basic hematological'
p2886
aS'HBsAgHBcAg vaccine'
p2887
aS'tabulated by time'
p2888
aS'related to any'
p2889
aS'children'
p2890
aS'2R bulbs'
p2891
aS'monitored over'
p2892
aS'two seroprotected'
p2893
aS'frequent adverse events'
p2894
aS'entire core antigen'
p2895
aS'events predominated'
p2896
aS'novel adjuvants gene'
p2897
aS'cells APCs'
p2898
aS'HBcAg had'
p2899
aS'risk factors'
p2900
aS'M cell'
p2901
aS'liter'
p2902
aS'geometric mean anti'
p2903
aS'1 to vaccine'
p2904
aS'induce'
p2905
aS'All reactions'
p2906
aS'get 25'
p2907
aS'device Also'
p2908
aS'HBcAg nasal'
p2909
aS'viral clearance'
p2910
aS'difference'
p2911
aS'similar proportion'
p2912
aS'head tilted'
p2913
aS'any adverse event'
p2914
aS'children became chronic'
p2915
aS'90 days following'
p2916
aS'list'
p2917
aS'prolonged'
p2918
aS'recipients one month'
p2919
aS'were registered Only'
p2920
aS'HBsAg used'
p2921
aS'small'
p2922
aS'infection resolving spontaneously'
p2923
aS'vaccines vaccines administered'
p2924
aS'surveillance methods Concurrent'
p2925
aS'revealed neither'
p2926
aS'antibodies and 25'
p2927
aS'seroprotective antibody titers'
p2928
aS'medical monitor'
p2929
aS'Similarly further assays'
p2930
aS'within 6 months'
p2931
aS'parenteral administered'
p2932
aS'Havana Cuba licensed'
p2933
aS'good safety'
p2934
aS'functioning'
p2935
aS'very distressing'
p2936
aS'enough to cause'
p2937
aS'immunization sera Only'
p2938
aS'10 l per'
p2939
aS'hour after each'
p2940
aS'reconstituted with peripheral'
p2941
aS'Engineering Biotechnology Havana'
p2942
aS'presence'
p2943
aS'samples All'
p2944
aS'behavioral risk factors'
p2945
aS'vomiting'
p2946
aS'events reported'
p2947
aS'animals under'
p2948
aS'HB CIGB'
p2949
aS'excess'
p2950
aS'planned medical consultations'
p2951
aS'nasal drug behavioral'
p2952
aS'significant acute'
p2953
aS'rate exceeded 15'
p2954
aS'immunity against HBV'
p2955
aS'Phase II'
p2956
aS'concluded at day'
p2957
aS'allows'
p2958
aS'after treatment'
p2959
aS'levels of anti'
p2960
aS'vaccine studies'
p2961
aS'novel routes'
p2962
aS'period and severity'
p2963
aS'antibody responses against'
p2964
aS'0 6ml'
p2965
aS'g Miacalcin nasal'
p2966
aS'dose injection'
p2967
aS'chronically infected'
p2968
aS'involved in collection'
p2969
aS'toxicity'
p2970
aS'All subjects received'
p2971
aS'patients resolving'
p2972
aS'more than 400'
p2973
aS'were also collected'
p2974
aS'volunteers Written informed'
p2975
aS'placebo group Individuals'
p2976
aS'pockets enable'
p2977
aS'anosmia nasal'
p2978
aS'immunoenhancing'
p2979
aS'surveillance methods'
p2980
aS'events within'
p2981
aS'commercial recombinant HBcAg'
p2982
aS'immunosuppressive disorders'
p2983
aS'trained'
p2984
aS'calcitonin salmon Novartis'
p2985
aS'mononuclear'
p2986
aS'containing recombinant hepatitis'
p2987
aS'alkaline phosphatase conjugate'
p2988
aS'B cell activator'
p2989
aS'clearly demonstrates'
p2990
aS'l for analysis'
p2991
aS'interval protocol'
p2992
aS'CTL level'
p2993
aS'intervention to prevent'
p2994
aS'received either NASVAC'
p2995
aS'geometric mean antibody'
p2996
aS'available for testing'
p2997
aS'were requested'
p2998
aS'outpatient'
p2999
aS'Drug Quality Control'
p3000
aS'tested'
p3001
aS'anti HBs ELISA'
p3002
aS'were mild self'
p3003
aS'cell dependent'
p3004
aS'Cuba licensed hepatitis'
p3005
aS'drug over'
p3006
aS'administration of successive'
p3007
aS'avoid anterior'
p3008
aS'strong HBV core'
p3009
aS'mean antibody'
p3010
aS'placebo controlled double'
p3011
aS'support further phase'
p3012
aS'l and high'
p3013
aS'nine'
p3014
aS'mostly reported during'
p3015
aS'any symptom'
p3016
aS'well coated'
p3017
aS'fever chills headache'
p3018
aS'volunteer received either'
p3019
aS'include combined'
p3020
aS'antigens Rates'
p3021
aS'group sample size'
p3022
aS'observation period concluded'
p3023
aS'All blood samples'
p3024
aS'potential therapeutic use'
p3025
aS'minimum'
p3026
aS'higher than'
p3027
aS'numbers'
p3028
aS'tract'
p3029
aS'sense'
p3030
aS'HBsAg immunogenicity'
p3031
aS'activated B cells'
p3032
aS'developed antibodies'
p3033
aS'inoculation under sterile'
p3034
aS'against both antigens'
p3035
aS'baseline all participants'
p3036
aS'antibodies against HBsAg'
p3037
aS'fluorigenic substrate'
p3038
aS'defined as concentration'
p3039
aS'multi specific'
p3040
aS'hypo responders'
p3041
aS'titer Anti'
p3042
aS'cases of fever'
p3043
aS'l in such'
p3044
aS'activator'
p3045
aS'routine use'
p3046
aS'plant'
p3047
aS'sandwich'
p3048
aS'percentages were'
p3049
aS'mild No development'
p3050
aS's head tilted'
p3051
aS'known nasally administered'
p3052
aS'true adverse'
p3053
aS'otorhinolaryngologist performed periodical'
p3054
aS'two seroprotected vaccine'
p3055
aS'buffer'
p3056
aS'enables antigens'
p3057
aS'Withdrawal'
p3058
aS'There were also'
p3059
aS'l based'
p3060
aS'results indicated'
p3061
aS'recombinant full length'
p3062
aS'ELISA kits Samples'
p3063
aS'rhinorrhea nasal stuffiness'
p3064
aS'superior to 95'
p3065
aS'chemistries'
p3066
aS'chronically infected patients'
p3067
aS'transient nasal'
p3068
aS'failures included persistently'
p3069
aS'safety and preliminary'
p3070
aS'T cell dependent'
p3071
aS'signs nor'
p3072
aS'enabling activated'
p3073
aS'specific post inoculation'
p3074
aS'group included sneezing'
p3075
aS'cell activator'
p3076
aS'between 18'
p3077
aS'made actively'
p3078
aS'signs'
p3079
aS'HBsAgHBcAg vaccine candidate'
p3080
aS'gratefully acknowledge Enrique'
p3081
aS'20'
p3082
aS'5ml Participants allocated'
p3083
aS'luminal surface'
p3084
aS'UMELISA plates 10'
p3085
aS'nasal immunization'
p3086
aS'moderate adverse'
p3087
aS'detected'
p3088
aS'were available'
p3089
aS'Local site adverse'
p3090
aS'volunteer generating more'
p3091
aS'placebo developed'
p3092
aS'antibody response'
p3093
aS'HBsAg mixed'
p3094
aS'drugs of protein'
p3095
aS'2R'
p3096
aS'effective approach'
p3097
aS'baseline 30 days'
p3098
aS'encouraging'
p3099
aS'medicine toxicology'
p3100
aS'unexpected or severe'
p3101
aS'Immunoassay Center'
p3102
aS'cell pockets enable'
p3103
aS'generating more'
p3104
aS'natural HBsAg subtype'
p3105
aS'g influenza'
p3106
aS'HBcAg Biokit'
p3107
aS'seroprotected vaccine recipients'
p3108
aS'became chronic'
p3109
aS'palate itching rhinorrhea'
p3110
aS'determine mucosal'
p3111
aS'antibodies 17'
p3112
aS'always'
p3113
aS'assistance and helpful'
p3114
aS'Further antigenicity studies'
p3115
aS'Only anti'
p3116
aS'did'
p3117
aS'collection of any'
p3118
aS'obtaining written informed'
p3119
aS'found'
p3120
aS'difficult'
p3121
aS'were collected'
p3122
aS'characterized'
p3123
aS'defects'
p3124
aS'excess over'
p3125
aS'Following administration'
p3126
aS'tilted'
p3127
aS'weight'
p3128
aS'undetectable'
p3129
aS'HBsAg antigen'
p3130
aS'considered statistically significant'
p3131
aS'present formulation Phase'
p3132
aS'temperature 39'
p3133
aS'antibodies Thus most'
p3134
aS'moderate and severe'
p3135
aS'licensed nasal vaccine'
p3136
aS'moderate symptom bothersome'
p3137
aS'20 of healthy'
p3138
aS'volunteers Written'
p3139
aS'Drug Administration'
p3140
aS'permanent disability'
p3141
aS'low responders anti'
p3142
aS'toxicological studies'
p3143
aS'vomiting diarrhea'
p3144
aS'29'
p3145
aS'frequently reported'
p3146
aS'months of study'
p3147
aS'Geometric mean anti'
p3148
aS'study one'
p3149
aS'mucosal irritating potential'
p3150
aS'severe Local site'
p3151
aS'age Volunteers were'
p3152
aS'issue'
p3153
aS'transport antigens'
p3154
aS'renal dialysis'
p3155
aS'each treatment'
p3156
aS'patients or chronic'
p3157
aS'According'
p3158
aS'mild symptom present'
p3159
aS'specialized mechanisms'
p3160
aS'Phase II clinical'
p3161
aS'Nine'
p3162
aS'19 included'
p3163
aS'immunity against HBcAg'
p3164
aS'mucosal blood vessel'
p3165
aS'registered Only two'
p3166
aS'phosphate buffer without'
p3167
aS'allocation'
p3168
aS'antigenic'
p3169
aS'single otorhinolaryngologist performed'
p3170
aS'fever were registered'
p3171
aS'studies HBcAg'
p3172
aS'age Volunteers'
p3173
aS'seroprotective antibody'
p3174
aS'currently licensed'
p3175
aS'g purified'
p3176
aS'accession number X02763'
p3177
aS'Recombinant HBcAg'
p3178
aS'Severe reactions'
p3179
aS'major'
p3180
aS'consultations'
p3181
aS'probability'
p3182
aS'resulting HBcAg'
p3183
aS'0 73 provided'
p3184
aS'reacts with solid'
p3185
aS'Quality Control'
p3186
aS'any clinical'
p3187
aS'detection of total'
p3188
aS'two participants completed'
p3189
aS'eight recipients'
p3190
aS'mouth Two applications'
p3191
aS'including antigen'
p3192
aS'trial no formal'
p3193
aS'mixture of 50g'
p3194
aS'HBsAg significantly'
p3195
aS'cell and antibody'
p3196
aS'threatening'
p3197
aS'least'
p3198
aS'changes in animals'
p3199
aS'Dickinson were filled'
p3200
aS'well documented'
p3201
aS'majority'
p3202
aS'compartment'
p3203
aS'9 sterile'
p3204
aS'chills headache muscle'
p3205
aS'participants needed'
p3206
aS'dose and between'
p3207
aS'general reaction'
p3208
aS'react with antibodies'
p3209
aS'approximately 500DC'
p3210
aS'immunogenicity profile'
p3211
aS'undetectable anti HBs'
p3212
aS'immediate'
p3213
aS'basal'
p3214
aS'neutralization'
p3215
aS'strong HBV'
p3216
aS'study support further'
p3217
aS'Food and Drug'
p3218
aS'defects in dendritic'
p3219
aS'Biokit'
p3220
aS'were mostly'
p3221
aS'against hepatitis'
p3222
aS'kind'
p3223
aS'75 By comparison'
p3224
aS'vial'
p3225
aS'30 Thirty days'
p3226
aS'characterized by electron'
p3227
aS'profile under'
p3228
aS'administered by day'
p3229
aS'vaccine and peptide'
p3230
aS'declare'
p3231
aS'antigen sampling including'
p3232
aS'Cuba All'
p3233
aS'CENATOX'
p3234
aS'HBeAg in saliva'
p3235
aS'immunogenicity Preclinical mouse'
p3236
aS'72hours'
p3237
aS'fixed volume'
p3238
aS'Dawley rats revealed'
p3239
aS'fever were'
p3240
aS'period concluded'
p3241
aS'showing antibody levels'
p3242
aS'glycosylated form HBcAg'
p3243
aS'dendritic'
p3244
aS'categorized'
p3245
aS'0038 All'
p3246
aS'assay anti'
p3247
aS'antibodies against'
p3248
aS'C until'
p3249
aS'virus control Recombinant'
p3250
aS'using similar surveillance'
p3251
aS'immunodominant antigen'
p3252
aS'internal'
p3253
aS'Baseline comparability'
p3254
aS'achieved anti HBs'
p3255
aS'after treatment display'
p3256
aS'specific Th cell'
p3257
aS'Written informed consent'
p3258
aS'added'
p3259
aS'severity mild'
p3260
aS'flu vaccine'
p3261
aS'intensity and 98'
p3262
aS'reach'
p3263
aS'developed antibodies against'
p3264
aS'react'
p3265
aS'commercial ultramicroanalytic enzyme'
p3266
aS'73'
p3267
aS'moderate symptom'
p3268
aS'approved'
p3269
aS'recombinant HBcAg particles'
p3270
aS'given 15 minutes'
p3271
aS'trial Nine participants'
p3272
aS'immunomodulatory effect'
p3273
aS'were healthy'
p3274
aS'reported nasal'
p3275
aS'get 25 seroprotection'
p3276
aS'vaccine Heberbiovac'
p3277
aS'Local adverse'
p3278
aS'graded as severe'
p3279
aS'formulation Sterile'
p3280
aS'recipients one'
p3281
aS'emitted fluorescence'
p3282
aS'authors'
p3283
aS'basal surface'
p3284
aS'aches decreased appetite'
p3285
aS'All sera were'
p3286
aS'attention Serious'
p3287
aS'samples were evaluated'
p3288
aS'candidate administered'
p3289
aS'balanced format'
p3290
aS'other commercial anti'
p3291
aS'impact'
p3292
aS'purity superior'
p3293
aS'parameters'
p3294
aS'64 8IU'
p3295
aS'severe symptoms'
p3296
aS'until use'
p3297
aS'any other nasal'
p3298
aS'basic hematological parameters'
p3299
aS'minutes apart All'
p3300
aS'HBs 10IU'
p3301
aS'prior inoculation'
p3302
aS'surface through'
p3303
aS'Thirty'
p3304
aS'immunogenicity of full'
p3305
aS'antigens by nasal'
p3306
aS'Geometric mean'
p3307
aS'event profile'
p3308
aS'assigned arbitrarily'
p3309
aS'instructed to measure'
p3310
aS'human sera'
p3311
aS'closely'
p3312
aS'male adults between'
p3313
aS'were considered hyper'
p3314
aS'anti HBs protective'
p3315
aS'candidate containing'
p3316
aS'evaluated during'
p3317
aS'State Center'
p3318
aS'HBsAg titer Anti'
p3319
aS'only 30'
p3320
aS'HBs ELISA'
p3321
aS'common'
p3322
aS'rhinorrhea nasal'
p3323
aS'administration also'
p3324
aS'subjects reporting adverse'
p3325
aS'residence time'
p3326
aS'both cases'
p3327
aS'vaccines plant derived'
p3328
aS'plasmid containing'
p3329
aS'Enrique'
p3330
aS'very encouraging taking'
p3331
aS'severe Clinically significant'
p3332
aS'nasal bleeding Solicited'
p3333
aS'Neither'
p3334
aS'trial Nine'
p3335
aS'allowed expiration'
p3336
aS'nasal ulceration'
p3337
aS'97 of adverse'
p3338
aS'kits Samples'
p3339
aS'immunization sera'
p3340
aS'77 recorded'
p3341
aS'currently'
p3342
aS'diluted'
p3343
aS'event There'
p3344
aS'immediate adverse'
p3345
aS'g Miacalcin'
p3346
aS'tolerated safe'
p3347
aS'DC Additionally'
p3348
aS'neither clinical'
p3349
aS'outcomes were'
p3350
aS'corroborates previous findings'
p3351
aS'obtaining written'
p3352
aS'products or immunoglobulin'
p3353
aS'other well'
p3354
aS'study entry'
p3355
aS'8IU l All'
p3356
aS'after vaccine administration'
p3357
aS'nostril were'
p3358
aS'sera Only'
p3359
aS'itching anosmia'
p3360
aS'2000 Among'
p3361
aS'peripheral blood'
p3362
aS'were kept'
p3363
aS'HBV specific immune'
p3364
aS'nucleoprotein in trace'
p3365
aS'headache muscle'
p3366
aS'antibody levels 100IU'
p3367
aS'HBs in sera'
p3368
aS'novel hepatitis'
p3369
aS'immunotherapy'
p3370
aS'became'
p3371
aS'severity Binomial'
p3372
aS'80 90'
p3373
aS'toxicology'
p3374
aS'event rate'
p3375
aS'study products'
p3376
aS'arbitrarily'
p3377
aS'point'
p3378
aS'order to increase'
p3379
aS'protective anti'
p3380
aS'congestion'
p3381
aS'recorded during 90'
p3382
aS'patient with high'
p3383
aS'were reported during'
p3384
aS'populations known'
p3385
aS'high mucosal nasal'
p3386
aS'antibody against'
p3387
aS'multi specific helper'
p3388
aS'vessel'
p3389
aS'candidate formulated'
p3390
aS'rabbits with induction'
p3391
aS'6 months'
p3392
aS'participants received'
p3393
aS'between 24h'
p3394
aS'venipuncture for measurement'
p3395
aS'doctor s visits'
p3396
aS'height between vaccine'
p3397
aS'strategy'
p3398
aS'reduction'
p3399
aS'ensured'
p3400
aS'All anti HBs'
p3401
aS'vaccine recipients according'
p3402
aS'detection of cellular'
p3403
aS'allows interaction'
p3404
aS'annoying'
p3405
aS'abnormalities in clinical'
p3406
aS'one hyper responder'
p3407
aS'trained physician'
p3408
aS'both antigens'
p3409
aS'study in 19'
p3410
aS'Sterile physiologic saline'
p3411
aS'occurred during'
p3412
aS'acemannan Whether'
p3413
aS'liver'
p3414
aS'titers of more'
p3415
aS'Preclinical toxicological'
p3416
aS'developments'
p3417
aS'screening visit'
p3418
aS'highest'
p3419
aS'cause'
p3420
aS'resulting'
p3421
aS'solid'
p3422
aS'safe and immunogenic'
p3423
aS'enrollment'
p3424
aS'coated with commercial'
p3425
aS'well known'
p3426
aS'vaccine allocation'
p3427
aS'antibody tests against'
p3428
aS'behavior'
p3429
aS'Exposure'
p3430
aS'resolving within 72h'
p3431
aS'Becton Dickinson were'
p3432
aS'Furthermore local'
p3433
aS'nurse sprayed'
p3434
aS'37'
p3435
aS'subjects signed'
p3436
aS'volunteers were aware'
p3437
aS'binding'
p3438
aS'study after'
p3439
aS'production facilities'
p3440
aS'display strong'
p3441
aS'immunomodulatory'
p3442
aS'during 90'
p3443
aS'commonly'
p3444
aS'recipients achieved anti'
p3445
aS'seroprotected vaccine'
p3446
aS'reach 75'
p3447
aS'alone'
p3448
aS'aches'
p3449
aS'rate increased'
p3450
aS'estimate'
p3451
aS'reporting of adverse'
p3452
aS'fashion on code'
p3453
aS'studies were'
p3454
aS'authors thank'
p3455
aS'nausea vomiting diarrhea'
p3456
aS'weak HBV specific'
p3457
aS'negative result'
p3458
aS'conflict'
p3459
aS'influenza nasal'
p3460
aS'g HBsAg mixed'
p3461
aS'7 of them'
p3462
aS'performed periodical examinations'
p3463
aS'Miacalcin'
p3464
aS'nasally parenteral administered'
p3465
aS'48hours on administration'
p3466
aS'conducted in Sprague'
p3467
aS'antibody titers against'
p3468
aS'mild self limiting'
p3469
aS'severe Severe reactions'
p3470
aS'systemic reactions 71'
p3471
aS'HBcAg Individuals were'
p3472
aS'did not increase'
p3473
aS'older'
p3474
aS'percentages'
p3475
aS'negative for HBsAg'
p3476
aS'responder volunteer'
p3477
aS'sera Briefly UMELISA'
p3478
aS'clinically significant'
p3479
aS'achieved antibody'
p3480
aS'polyclonal'
p3481
aS'anti HBs 100IU'
p3482
aS'negative immunomodulatory'
p3483
aS'entry'
p3484
aS'clearance'
p3485
aS'Quality'
p3486
aS'adverse events 58'
p3487
aS'carrier state'
p3488
aS'nucleoprotein'
p3489
aS'test for proportions'
p3490
aS'CECMED'
p3491
aS'administered using'
p3492
aS'given 15'
p3493
aS'sera were available'
p3494
aS'devices and methodologies'
p3495
aS'competitive'
p3496
aS'cells transport antigens'
p3497
aS'administration enables antigens'
p3498
aS'against HBsAg 10IU'
p3499
aS'rate exceeded'
p3500
aS'useful'
p3501
aS'recombinant HBsAg subtype'
p3502
aS'Written informed'
p3503
aS'immunoenzymatic assay'
p3504
aS'HBs ELISA kits'
p3505
aS'nasal route showing'
p3506
aS'schedule Following'
p3507
aS'corroborates'
p3508
aS'added reacting'
p3509
aS'specific immune response'
p3510
aS'g of HBcAg'
p3511
aS'12h post immunization'
p3512
aS'estimate each'
p3513
aS'same volume'
p3514
aS'immediate adverse events'
p3515
aS'increase in frequency'
p3516
aS'transparent liquid'
p3517
aS'doses Local adverse'
p3518
aS'liver failure'
p3519
aS'format'
p3520
aS'situation'
p3521
aS'included fever chills'
p3522
aS'HBcAg nucleic acids'
p3523
aS'support further'
p3524
aS'Finlay Hospital Havana'
p3525
aS'showing antibody'
p3526
aS'purified recombinant full'
p3527
aS'0 05'
p3528
aS'allocated to placebo'
p3529
aS'13 excess over'
p3530
aS'diseases immunosuppressive'
p3531
aS'reacting'
p3532
aS'adjustments were made'
p3533
aS'respect to anti'
p3534
aS'signal'
p3535
aS'hospitalizations were also'
p3536
aS'only comprises'
p3537
aS'reported in recipients'
p3538
aS'developed anti'
p3539
aS'over nasally parenteral'
p3540
aS'primary APCs'
p3541
aS'allocation All aspects'
p3542
aS'conducted to characterize'
p3543
aS'Serious adverse'
p3544
aS'low responders'
p3545
aS'nausea vomiting'
p3546
aS'Dawley'
p3547
aS'steroid anti'
p3548
aS'controlled double blinded'
p3549
aS'normal functioning may'
p3550
aS'neutralization using'
p3551
aS'delivered'
p3552
aS'reconstituted'
p3553
aS'rates of seroprotection'
p3554
aS'incubated with samples'
p3555
aS'interest to declare'
p3556
aS'fatal or life'
p3557
aS'nasal bleeding'
p3558
aS'particle to more'
p3559
aS'derived vaccines'
p3560
aS'immunization Withdrawal'
p3561
aS'any immediate'
p3562
aS'nose'
p3563
aS'hyper responder volunteer'
p3564
aS'patient'
p3565
aS'fifth vaccine dose'
p3566
aS'dose at time'
p3567
aS'matched pre'
p3568
aS'treatment display strong'
p3569
aS'vaccine and placebo'
p3570
aS'Dickinson Depending'
p3571
aS'helper and cytotoxic'
p3572
aS'reasonably immunogenic'
p3573
aS'Chronic HBV'
p3574
aS'hepatitis B surface'
p3575
aS'saliva from one'
p3576
aS'body system Adverse'
p3577
aS'after inoculation'
p3578
aS'apparent abnormalities'
p3579
aS'range'
p3580
aS'male adult'
p3581
aS'4 C until'
p3582
aS'remaining 19'
p3583
aS'successive vaccine'
p3584
aS'immunization for any'
p3585
aS'comparison licensed HBV'
p3586
aS'annoying may'
p3587
aS'anti HBs 10IU'
p3588
aS'assay for qualitative'
p3589
aS'candidate developed'
p3590
aS'formal sample'
p3591
aS'antigen uptake'
p3592
aS'Only two moderate'
p3593
aS'recent exposure'
p3594
aS'all participants prior'
p3595
aS'reactions 71'
p3596
aS'enhancement of antiviral'
p3597
aS'computer'
p3598
aS'luminal'
p3599
aS'long'
p3600
aS'after obtaining'
p3601
aS'hepatocellular carcinoma'
p3602
aS'there were'
p3603
aS'time 37'
p3604
aS'result On completion'
p3605
aS'general reaction category'
p3606
aS'self limited'
p3607
aS'two moderate'
p3608
aS'nor induced'
p3609
aS'virus after'
p3610
aS'registered'
p3611
aS'19 participants were'
p3612
aS'X02763 HBsAg'
p3613
aS'Severe'
p3614
aS'calcitonin salmon'
p3615
aS'injection'
p3616
aS'HBs only'
p3617
aS'further immunogenicity'
p3618
aS'group Sneezing palate'
p3619
aS'such as older'
p3620
aS'commonly reported nasal'
p3621
aS'Heberbiovac HB CIGB'
p3622
aS'seroconversion after'
p3623
aS'given via'
p3624
aS'co administered HBsAg'
p3625
aS'criterion for protection'
p3626
aS'increased to 75'
p3627
aS'associated'
p3628
aS'Local site reactions'
p3629
aS'minutes'
p3630
aS'administration of each'
p3631
aS'participants were randomly'
p3632
aS'4 pre existing'
p3633
aS'continuous variables Adverse'
p3634
aS'quantification'
p3635
aS'generated list'
p3636
aS'second vaccine'
p3637
aS'immunosorbent assay ELISA'
p3638
aS'microscopy EM analysis'
p3639
aS'mouse studies'
p3640
aS'carcinoma'
p3641
aS'e g Miacalcin'
p3642
aS'amounts'
p3643
aS'screen failures'
p3644
aS'studied dose'
p3645
aS'over systemic'
p3646
aS'transport'
p3647
aS'visits and hospitalizations'
p3648
aS'gratefully acknowledge'
p3649
aS'HBcAg Individuals'
p3650
aS'fourth immunization Withdrawal'
p3651
aS'positive response'
p3652
aS'most commonly'
p3653
aS'15 participants'
p3654
aS'activity of HBcAg'
p3655
aS'tests 4 pre'
p3656
aS'generated'
p3657
aS'secondary outcomes'
p3658
aS'resulting HBcAg had'
p3659
aS'further assays'
p3660
aS'nucleic acids bound'
p3661
aS'Participants were'
p3662
aS'immunogenic in healthy'
p3663
aS'samples All anti'
p3664
aS'mucosal immune system'
p3665
aS'methodologies'
p3666
aS'fluorescence'
p3667
aS'volumes of samples'
p3668
aS'placebo solution All'
p3669
aS'network of approximately'
p3670
aS'high HBsAg titer'
p3671
aS'recorded adverse events'
p3672
aS'group No unexpected'
p3673
aS'HBs only 30'
p3674
aS'study personnel'
p3675
aS'international'
p3676
aS'developed seroprotective'
p3677
aS'having'
p3678
aS'time of immunization'
p3679
aS'code'
p3680
aS'partial'
p3681
aS'resolving acute'
p3682
aS'group remained positive'
p3683
aS's head'
p3684
aS'existing'
p3685
aS'fourth dose'
p3686
aS'Immunoassay'
p3687
aS'Biotechnology Havana'
p3688
aS'were not substantially'
p3689
aS'third dose'
p3690
aS'mild symptom'
p3691
aS'consultations or doctor'
p3692
aS'mild moderate'
p3693
aS'l per nostril'
p3694
aS'resolving within'
p3695
aS'young'
p3696
aS'between study'
p3697
aS'chronic infection resolving'
p3698
aS'excluded'
p3699
aS'fatal'
p3700
aS'One recipient'
p3701
aS'remained positive'
p3702
aS'adjuvants gene vaccine'
p3703
aS'HBV vaccine Heberbiovac'
p3704
aS'random'
p3705
aS'most frequent'
p3706
aS'group 59'
p3707
aS'vaccine allocation All'
p3708
aS'25 seroprotection'
p3709
aS'venipuncture'
p3710
aS'HBs 10 100IU'
p3711
aS'state of unresponsiveness'
p3712
aS'vaccine and were'
p3713
aS'mucosal immunization further'
p3714
aS'electron'
p3715
aS'cellular'
p3716
aS'functional defects'
p3717
aS'young adults 30'
p3718
aS'cell and cytotoxic'
p3719
aS'100IU l Sera'
p3720
aS'nausea'
p3721
aS'recombinant Heberbiovac HB'
p3722
aS'entire'
p3723
aS'core HBc specific'
p3724
aS'dose of HBsAg'
p3725
aS'induced local damage'
p3726
aS'peripheral blood mononuclear'
p3727
aS'HBsAg subtype CIGB'
p3728
aS'race'
p3729
aS'7 years'
p3730
aS'Adverse events did'
p3731
aS'levels 100IU'
p3732
aS'concluded'
p3733
aS'CIGB production facilities'
p3734
aS'number X02763 HBsAg'
p3735
aS'events as well'
p3736
aS'length recombinant'
p3737
aS'bleeding'
p3738
aS'distressing interference'
p3739
aS'kept under observation'
p3740
aS'responder volunteer generating'
p3741
aS'State'
p3742
aS'included persistently abnormal'
p3743
aS'study No cases'
p3744
aS'surface network'
p3745
aS'transformed previously'
p3746
aS'group sample'
p3747
aS'limiting resolving within'
p3748
aS'anti HBV'
p3749
aS'cutaneous'
p3750
aS'clinical data'
p3751
aS'post immunization Solicited'
p3752
aS'were similar'
p3753
aS'HBV specific'
p3754
aS'consistently'
p3755
aS'code labeled matched'
p3756
aS'white race'
p3757
aS'values'
p3758
aS'hematology values were'
p3759
aS'stuffiness or congestion'
p3760
aS'thin'
p3761
aS'body'
p3762
aS'developed seroprotective antibody'
p3763
aS'doses Adverse'
p3764
aS'status after'
p3765
aS'years range 18'
p3766
aS'other particulate antigens'
p3767
aS'volunteers inoculated'
p3768
aS'strain W3110'
p3769
aS'other symptoms'
p3770
aS'different than'
p3771
aS'functioning may'
p3772
aS'size nine participants'
p3773
aS'vaccine administration'
p3774
aS'consideration'
p3775
aS'any study procedure'
p3776
aS'Participants were kept'
p3777
aS'compromised'
p3778
aS'39'
p3779
aS'38'
p3780
aS'PBMCs'
p3781
aS'involved'
p3782
aS'distribution point'
p3783
aS'fully demonstrated'
p3784
aS'total serum'
p3785
aS'volume of 125'
p3786
aS'vaccines or had'
p3787
aS'vial contained'
p3788
aS'healthy young'
p3789
aS'anti HBs equal'
p3790
aS'examinations'
p3791
aS'formulated'
p3792
aS'all other reactions'
p3793
aS'fluorescent substrate'
p3794
aS'molecule as revealed'
p3795
aS'titer Anti HBs'
p3796
aS'outcomes'
p3797
aS'HBsAg immunogenicity Preclinical'
p3798
aS'comparison with other'
p3799
aS'unresponsiveness'
p3800
aS'sensitivity to any'
p3801
aS'4 pre'
p3802
aS'plant derived'
p3803
aS'each treatment group'
p3804
aS'acute or chronic'
p3805
aS'neither irritating'
p3806
aS'results of preclinical'
p3807
aS'inoculation adverse reactions'
p3808
aS'severe Severe'
p3809
aS'anti inflammatory'
p3810
aS'chemistry and basic'
p3811
aS'duplicate'
p3812
aS'examination'
p3813
aS'days post immunization'
p3814
aS'secondary outcomes were'
p3815
aS'HBcAg CIGB Havana'
p3816
aS'anti inflammatory analgesics'
p3817
aS'first inoculation using'
p3818
aS'10 100IU'
p3819
aS'computer generated'
p3820
aS'Miacalcin nasal'
p3821
aS'occurred'
p3822
aS'transient'
p3823
aS'history of sensitivity'
p3824
aS'rabbit'
p3825
aS'vaccine candidate formulated'
p3826
aS'local reaction'
p3827
aS'nasal conditions'
p3828
aS'randomized and received'
p3829
aS'evident and corroborates'
p3830
aS'animals'
p3831
aS'known nasally'
p3832
aS'immunodominant'
p3833
aS'until use Nasal'
p3834
aS'subtype CIGB'
p3835
aS'Solid phase antigen'
p3836
aS'were closely assessed'
p3837
aS'mucosal blood'
p3838
aS'field'
p3839
aS'positive for anti'
p3840
aS'profile Recent advances'
p3841
aS'Miacalcin nasal spray'
p3842
aS'pre study'
p3843
aS'study drug'
p3844
aS'administered through novel'
p3845
aS'calculation'
p3846
aS'adults and 80'
p3847
aS'proportions'
p3848
aS'symptom present'
p3849
aS'Written'
p3850
aS'anosmia nasal ulceration'
p3851
aS'mononuclear cells PBMCs'
p3852
aS'samples Solid phase'
p3853
aS'particles'
p3854
aS'similar proportion hypo'
p3855
aS'0 2IU'
p3856
aS'doses Adverse events'
p3857
aS'irritating potential'
p3858
aS'during 90 applied'
p3859
aS'vessel status'
p3860
aS'dependent'
p3861
aS'90 day'
p3862
aS'adapted'
p3863
aS'candidate showed'
p3864
aS'using similar'
p3865
aS'hypothesis testing'
p3866
aS'also collected'
p3867
aS'developed anti HBs'
p3868
aS'6ml'
p3869
aS'any local reaction'
p3870
aS'43 subjects'
p3871
aS'discomfort'
p3872
aS'limiting and disappeared'
p3873
aS'without adjuvants'
p3874
aS'any immediate adverse'
p3875
aS'Furthermore participants were'
p3876
aS'recipients as early'
p3877
aS'vaccine doses Adverse'
p3878
aS'binding of HBsAg'
p3879
aS'mice and rabbits'
p3880
aS'study were'
p3881
aS'even without adjuvants'
p3882
aS'One'
p3883
aS'Furthermore participants'
p3884
aS'Nasal administration enables'
p3885
aS'study clearly demonstrates'
p3886
aS'adjustments were'
p3887
aS'competitive sequential'
p3888
aS'Local adverse events'
p3889
aS'abnormalities visualized'
p3890
aS'significant events were'
p3891
aS'preclinical'
p3892
aS'produced'
p3893
aS'including'
p3894
aS'units per liter'
p3895
aS'All reactions were'
p3896
aS'administered by intranasal'
p3897
aS'chemistry'
p3898
aS'white race predominated'
p3899
aS'superior'
p3900
aS'mice with full'
p3901
aS'absent mild symptom'
p3902
aS'consent Individuals'
p3903
aS'reactions combined'
p3904
aS'each rate'
p3905
aS'were self'
p3906
aS'70IU'
p3907
aS'antigen sampling'
p3908
aS'specific active'
p3909
aS'g purified recombinant'
p3910
aS'accession number'
p3911
aS'physicians'
p3912
aS'study nurse sprayed'
p3913
aS'mechanisms'
p3914
aS'assessed by Fisher'
p3915
aS'prophylactic vaccines plant'
p3916
aS'Binomial distribution'
p3917
aS'Solid'
p3918
aS'years range'
p3919
aS'consent and underwent'
p3920
aS'symptom bothersome discomfort'
p3921
aS'functional'
p3922
aS'licensed nasal flu'
p3923
aS'interference with usual'
p3924
aS'two 25'
p3925
aS'study group remained'
p3926
aS'documented'
p3927
aS'high HBsAg'
p3928
aS'predominated over systemic'
p3929
aS'specific active immunotherapy'
p3930
aS'vaccine antigens NASVAC'
p3931
aS'adverse event There'
p3932
aS'route of immunization'
p3933
aS'participants during'
p3934
aS'epistaxis were'
p3935
aS'Biokit Barcelona'
p3936
aS'systemic adverse effects'
p3937
aS'induced serum'
p3938
aS'after immunization'
p3939
aS'determine mucosal irritating'
p3940
aS'blood vessel'
p3941
aS'any adjuvant'
p3942
aS'estimates and 95'
p3943
aS'clinically significant acute'
p3944
aS'core HBc'
p3945
aS'Thirty days'
p3946
aS'cell responses'
p3947
aS'profile under routine'
p3948
aS'Cuba licensed'
p3949
aS'inoculation adverse'
p3950
aS'exceeded'
p3951
aS'80'
p3952
aS'first dose'
p3953
aS'access Furthermore local'
p3954
aS'were given via'
p3955
aS'self limited HBV'
p3956
aS'rez'
p3957
aS'older individuals renal'
p3958
aS'clinical chemistry'
p3959
aS'other well known'
p3960
aS'l seroprotection percentage'
p3961
aS'controlled double'
p3962
aS'include'
p3963
aS'third vaccine dose'
p3964
aS'confirmed in further'
p3965
aS'medical attention Serious'
p3966
aS'formulation and placebo'
p3967
aS'first inoculation Blood'
p3968
aS'solid phase'
p3969
aS'reacts'
p3970
aS'HBV chronically'
p3971
aS'nasal spray device'
p3972
aS'intranasal route'
p3973
aS'serum antibody responses'
p3974
aS'group observation'
p3975
aS'performed however each'
p3976
aS'study procedure'
p3977
aS'70IU l One'
p3978
aS'mean age'
p3979
aS'candidate tested'
p3980
aS'backwards'
p3981
aS'mucosal immune'
p3982
aS'Sprague Dawley rats'
p3983
aS'after obtaining written'
p3984
aS'against HBV infection'
p3985
aS'HBs antibodies'
p3986
aS'e g influenza'
p3987
aS'event There were'
p3988
aS'chills'
p3989
aS'total anti HBc'
p3990
aS'were needed'
p3991
aS'plates 10'
p3992
aS'length HBcAg CIGB'
p3993
aS'sera block antigenic'
p3994
aS'rabbit anti'
p3995
aS'Administration'
p3996
aS'showed seroconversion against'
p3997
aS'spray devices Accuspray'
p3998
aS'58'
p3999
aS'planned medical'
p4000
aS'C terminal region'
p4001
aS'vaccine only comprises'
p4002
aS'mucosal nasal immunogenicity'
p4003
aS'reporting specific'
p4004
aS'promoter'
p4005
aS'antigenicity'
p4006
aS'reactions were defined'
p4007
aS'immunization Solicited adverse'
p4008
aS'systemic immunity elicited'
p4009
aS'discomfort enough'
p4010
aS'adult volunteers'
p4011
aS'antigens to access'
p4012
aS'analgesics non planned'
p4013
aS'0 0038'
p4014
aS'after vaccine'
p4015
aS'report in humans'
p4016
aS'pre existing'
p4017
aS'HBcAg to HBsAg'
p4018
aS'Volunteers were recruited'
p4019
aS'day period'
p4020
aS'1 hour after'
p4021
aS'limitations explained'
p4022
aS'inoculation Adverse events'
p4023
aS'flu vaccine using'
p4024
aS'Novartis'
p4025
aS'placebo developed antibodies'
p4026
aS'obtained by venipuncture'
p4027
aS'screening regarding'
p4028
aS'institution'
p4029
aS'independent antigen'
p4030
aS'blinded study'
p4031
aS'observed'
p4032
aS'vaccine studies HBcAg'
p4033
aS'nasal HBsAg'
p4034
aS'HBcAg nasal vaccine'
p4035
aS'size nine'
p4036
aS'obtained from all'
p4037
aS'any component'
p4038
aS'assays'
p4039
aS'consent Individuals were'
p4040
aS'each subject'
p4041
aS'calcitonin'
p4042
aS'salmon Novartis'
p4043
aS'elicit seroconversion'
p4044
aS'sera Only anti'
p4045
aS'distribution point estimates'
p4046
aS'cells transport'
p4047
aS'phase II'
p4048
aS'clinical studies'
p4049
aS'cytoplasm'
p4050
aS'them were requested'
p4051
aS'apart All'
p4052
aS'5 More'
p4053
aS'protective anti HBs'
p4054
aS'prevent permanent'
p4055
aS'derived vaccines vaccines'
p4056
aS'events included anterior'
p4057
aS'22nm'
p4058
aS'standard parenteral'
p4059
aS'first in human'
p4060
aS'headache both'
p4061
aS'HBcAg nucleic'
p4062
aS'HBcAg combined formulations'
p4063
aS'After'
p4064
aS'titers around 70IU'
p4065
aS'Center Havana Cuba'
p4066
aS'M cell pockets'
p4067
aS'well as hypo'
p4068
aS'chronic diseases'
p4069
aS'candidate were undertaken'
p4070
aS'unresponsiveness characteristic'
p4071
aS'were not available'
p4072
aS'worldwide'
p4073
aS'II clinical'
p4074
aS'injection and up'
p4075
aS'provided to participants'
p4076
aS'II studies'
p4077
aS'dose to achieve'
p4078
aS'inflammatory Th1 response'
p4079
aS'conditions occurred'
p4080
aS'antigens with DC'
p4081
aS'digestive'
p4082
aS'eight'
p4083
aS'posterior nasal dripping'
p4084
aS'nuisance'
p4085
aS'total dose'
p4086
aS'treatment group observation'
p4087
aS'HBsAg exploiting'
p4088
aS'events were tabulated'
p4089
aS'100 of vaccine'
p4090
aS'chronic patients'
p4091
aS'consequences'
p4092
aS'95 purity'
p4093
aS'further phase'
p4094
aS'schedule formulation'
p4095
aS'modulatory effect'
p4096
aS'headache both reports'
p4097
aS'hour after vaccine'
p4098
aS'immunotherapy in HBV'
p4099
aS'available for screening'
p4100
aS'125l per nostril'
p4101
aS'findings'
p4102
aS'comparison licensed'
p4103
aS'0038'
p4104
aS'developments to boost'
p4105
aS'local adverse event'
p4106
aS'negative immunomodulatory effect'
p4107
aS'immunopotentiating'
p4108
aS'participants completed'
p4109
aS'visualized'
p4110
aS'examinations with visualization'
p4111
aS'considered hyper'
p4112
aS'year 2000'
p4113
aS'Briefly anti'
p4114
aS'fourth immunization'
p4115
aS'placebo group Sneezing'
p4116
aS'Organization there'
p4117
aS'pre study screening'
p4118
aS'events between study'
p4119
aS'tolerance All'
p4120
aS'reporting of nasal'
p4121
aS'rash'
p4122
aS'including antigen uptake'
p4123
aS'under routine'
p4124
aS'most moderate symptom'
p4125
aS'vaccine such'
p4126
aS'achieve'
p4127
aS'approximately 500DC mm'
p4128
aS'C until use'
p4129
aS'center randomized placebo'
p4130
aS'peptide'
p4131
aS'28nm'
p4132
aS'g nasal'
p4133
aS'Whether'
p4134
aS'adults in order'
p4135
aS'disappeared within 72hours'
p4136
aS'severe symptoms very'
p4137
aS'were reported more'
p4138
aS'sterile phosphate buffer'
p4139
aS'had clinically significant'
p4140
aS'patients and immune'
p4141
aS'samples Solid'
p4142
aS'vaccine formulation consisting'
p4143
aS'antibody tests'
p4144
aS'given via nasal'
p4145
aS'anti HBc alkaline'
p4146
aS'baseline all'
p4147
aS'strong polyclonal'
p4148
aS'approach'
p4149
aS'assay ELISA'
p4150
aS'exceeded 15'
p4151
aS'samples were collected'
p4152
aS'hyper responder 100IU'
p4153
aS'phosphatase conjugate'
p4154
aS'potent immunogen even'
p4155
aS'fixed'
p4156
aS'site reactions were'
p4157
aS'e g nasal'
p4158
aS'derived recombinant HBsAg'
p4159
aS'study support'
p4160
aS'screening regarding chemical'
p4161
aS'acceptable local'
p4162
aS'humans'
p4163
aS'trace amounts'
p4164
aS'other reactions combined'
p4165
aS'HBsAg in mice'
p4166
aS'clinical adverse'
p4167
aS'display strong polyclonal'
p4168
aS'carriers of hepatitis'
p4169
aS'HBsAg significantly increases'
p4170
aS'sample size calculation'
p4171
aS'B cell'
p4172
aS'days All'
p4173
aS'digestive tract'
p4174
aS'HBV chronic'
p4175
aS'included anterior'
p4176
aS'cytokine response'
p4177
aS'HBs protective'
p4178
aS'investigators'
p4179
aS'any other symptoms'
p4180
aS'routine'
p4181
aS'were measured'
p4182
aS'cells to work'
p4183
aS'bothersome discomfort enough'
p4184
aS'recombinant hepatitis'
p4185
aS'dendritic cell populations'
p4186
aS'electron microscopy'
p4187
aS'size calculation'
p4188
aS'local reaction category'
p4189
aS'emitted'
p4190
aS'disorders or medication'
p4191
aS'immunization nor'
p4192
aS'single nasal'
p4193
aS'anti HBs alkaline'
p4194
aS'hypothesis'
p4195
aS'failure and hepatocellular'
p4196
aS'successive vaccine doses'
p4197
aS'responses against both'
p4198
aS'had no history'
p4199
aS'Also chronic HBV'
p4200
aS'phase II studies'
p4201
aS'nuisance at most'
p4202
aS'Individuals of white'
p4203
aS'parenteral HBV vaccine'
p4204
aS'taking'
p4205
aS'acknowledge'
p4206
aS'both reports'
p4207
aS'EM analysis Further'
p4208
aS'responder 100IU'
p4209
aS'anti HBs UMELISA'
p4210
aS'itching anosmia nasal'
p4211
aS'HBsAg or HBcAg'
p4212
aS'otorhinolaryngologist performed'
p4213
aS'site reactions'
p4214
aS'5 of seroprotected'
p4215
aS'Toxicology and Carlos'
p4216
aS'were estimated'
p4217
aS'animal studies'
p4218
aS'17 and inability'
p4219
aS'candidate demonstrated seroconversion'
p4220
aS'adverse events within'
p4221
aS'include combined prophylactic'
p4222
aS'posterior dripping'
p4223
aS'fact along'
p4224
aS'study clearly'
p4225
aS'Finally'
p4226
aS'administration enables'
p4227
aS'adults Local site'
p4228
aS'seroprotection percentage anti'
p4229
aS'immunity Nasal'
p4230
aS'human clinical trial'
p4231
aS'rates of local'
p4232
aS'methods Concurrent'
p4233
aS'trial were closely'
p4234
aS'one hyper'
p4235
aS'mucosal irritating'
p4236
aS'sequential immunoenzymatic'
p4237
aS'statistical analysis There'
p4238
aS'activator enabling activated'
p4239
aS'years There were'
p4240
aS'kept under'
p4241
aS'3 and epistaxis'
p4242
aS'days following'
p4243
aS'Research Ethics'
p4244
aS'monoclonal'
p4245
aS'muscle aches'
p4246
aS'dripping nasal'
p4247
aS'Drug Quality'
p4248
aS'detection of IgA'
p4249
aS'comprising HBsAg'
p4250
aS'successive reaction'
p4251
aS'sponsor institution Five'
p4252
aS'headache muscle aches'
p4253
aS'decreased'
p4254
aS'labeled matched'
p4255
aS'one month after'
p4256
aS'acute hepatitis'
p4257
aS'virus anti HBs'
p4258
aS'adverse events between'
p4259
aS'secretion of HBeAg'
p4260
aS'multi'
p4261
aS'hepatocellular'
p4262
aS'8 of vaccine'
p4263
aS'reported among individuals'
p4264
aS'statistical analysis'
p4265
aS'spray devices'
p4266
aS'other nasal drug'
p4267
aS'expiration'
p4268
aS'attention or severe'
p4269
aS'preliminary immunogenicity'
p4270
aS'systemic reactions'
p4271
aS'five vaccine doses'
p4272
aS'helper'
p4273
aS'Cuba and 50'
p4274
aS'inoculation using'
p4275
aS'cutaneous rash'
p4276
aS'completed'
p4277
aS'90 applied'
p4278
aS'mucosal adjuvant'
p4279
aS'specific immune'
p4280
aS'interference with normal'
p4281
aS'visualized in vaccine'
p4282
aS'symptoms very distressing'
p4283
aS'dual'
p4284
aS'random numbers'
p4285
aS'Rates of adverse'
p4286
aS'day 30 Thirty'
p4287
aS'Geometric'
p4288
aS'compartment protected'
p4289
aS'prior to any'
p4290
aS'blood screening'
p4291
aS'recording of adverse'
p4292
aS'supported'
p4293
aS'severe Local'
p4294
aS'infrequent Adverse'
p4295
aS'were given 15'
p4296
aS'abnormal baseline'
p4297
aS'units'
p4298
aS'formulations in healthy'
p4299
aS'further phase II'
p4300
aS'group No subjects'
p4301
aS'adults 30 days'
p4302
aS'antibody level'
p4303
aS'around 70IU'
p4304
aS'85 5 More'
p4305
aS'S protein'
p4306
aS'tolerated and reasonably'
p4307
aS'29 7 years'
p4308
aS'revealed neither clinical'
p4309
aS'placebo solution'
p4310
aS'administration of HBcAg'
p4311
aS'sera block'
p4312
aS'reactions were combined'
p4313
aS'international units'
p4314
aS'formulation in each'
p4315
aS'administration comprising'
p4316
aS'center'
p4317
aS'difficult to access'
p4318
aS'fully'
p4319
aS'Conversely'
p4320
aS'were tabulated'
p4321
aS'24h and 72h'
p4322
aS'failures'
p4323
aS'Chronic HBV infection'
p4324
aS'personnel'
p4325
aS'comparisons'
p4326
aS'muscle'
p4327
aS'applied doses 85'
p4328
aS'usual'
p4329
aS'subjects reporting specific'
p4330
aS'Baseline'
p4331
aS'77 adverse events'
p4332
aS'HBsAg HBcAg combined'
p4333
aS'Immunoassay Center Havana'
p4334
aS'recipients of other'
p4335
aS'subjects withdrew'
p4336
aS'salmon'
p4337
aS'HBcAg at day'
p4338
aS'were no differences'
p4339
aS'secreted protein'
p4340
aS'impaired'
p4341
aS'Barcelona Spain'
p4342
aS'inoculations'
p4343
aS'group observation period'
p4344
aS'variables Adverse'
p4345
aS'other licensed nasal'
p4346
aS'devices Accuspray Becton'
p4347
aS'achieved anti'
p4348
aS'10 of adults'
p4349
aS'immunoenhancing activity'
p4350
aS'were considered'
p4351
aS'values were found'
p4352
aS'transparent'
p4353
aS'antiviral therapies'
p4354
aS'reasons'
p4355
aS'potent B cell'
p4356
aS'l One'
p4357
aS'Despite'
p4358
aS'lymphocytes'
p4359
aS'severe Clinically'
p4360
aS'matched'
p4361
aS'decreased appetite nausea'
p4362
aS'inoculation and were'
p4363
aS'closely assessed'
p4364
aS'increased'
p4365
aS'tolerated and induced'
p4366
aS'immunization with hepatitis'
p4367
aS'mild self'
p4368
aS'were aware'
p4369
aS'9 sterile saline'
p4370
aS'increases'
p4371
aS'Food'
p4372
aS'recipients achieved'
p4373
aS'UMELISA plates'
p4374
aS'values were'
p4375
aS'each immunization'
p4376
aS'Further antigenicity'
p4377
aS'three doses'
p4378
aS'significant no adjustments'
p4379
aS'Sneezing palate'
p4380
aS'most moderate'
p4381
aS'mucosal immunogenicity'
p4382
aS'HB CIGB Havana'
p4383
aS'exploiting'
p4384
aS'qualitative'
p4385
aS'considered statistically'
p4386
aS'differences between vaccine'
p4387
aS'hosts'
p4388
aS'l per well'
p4389
aS'days post'
p4390
aS'infection In vaccine'
p4391
aS'Preclinical mouse'
p4392
aS'clearly evident'
p4393
aS'therapeutic'
p4394
aS'products were stored'
p4395
aS'significant persistent'
p4396
aS'hospitalizations'
p4397
aS'placebo received'
p4398
aS'underwent'
p4399
aS'schedule In two'
p4400
aS'balanced format using'
p4401
aS'baseline biochemistry'
p4402
aS'events were mostly'
p4403
aS'Dickinson were'
p4404
aS'effects predominated'
p4405
aS'relevant for virus'
p4406
aS'least one adverse'
p4407
aS'present formulation'
p4408
aS'cell responses against'
p4409
aS'reported nasal adverse'
p4410
aS'chronic carriage'
p4411
aS'monitored'
p4412
aS'consistently demonstrated'
p4413
aS'demonstrates'
p4414
aS'avoid'
p4415
aS'serum clinical'
p4416
aS'presenting cells APCs'
p4417
aS'were filled'
p4418
aS'candidate developed seroprotective'
p4419
aS'18 45'
p4420
aS'HBcAg immunomodulation'
p4421
aS'formulation and device'
p4422
aS'itching palate'
p4423
aS'head tilted backwards'
p4424
aS'bothersome discomfort'
p4425
aS'percentage anti HBc'
p4426
aS'limitations'
p4427
aS'probability of detecting'
p4428
aS'coated'
p4429
aS'used Genbank accession'
p4430
aS'length recombinant HBcAg'
p4431
aS'Center for Drug'
p4432
aS'outpatient basis'
p4433
aS'samples and reagents'
p4434
aS'6 13'
p4435
aS'adverse reaction'
p4436
aS'mucosal immunization'
p4437
aS'other developed anti'
p4438
aS'HBc UMELISA Immunoassay'
p4439
aS'stage'
p4440
aS'adults 30'
p4441
aS'fever chills'
p4442
aS'co purified'
p4443
aS'8 general'
p4444
aS'statistically significant'
p4445
aS'gene vaccine'
p4446
aS'carrier'
p4447
aS'candidate and 10'
p4448
aS'cytokine'
p4449
aS'time day'
p4450
aS'term consequences'
p4451
aS'Also chronic'
p4452
aS'neither irritating nor'
p4453
aS'HBcAg over'
p4454
aS'compromised hosts'
p4455
aS'Sera'
p4456
aS'Two'
p4457
aS'12h post'
p4458
aS'spontaneously and patients'
p4459
aS'nasal conditions occurred'
p4460
aS'device Also chronic'
p4461
aS'test for continuous'
p4462
aS'specialized'
p4463
aS'liquid Each vial'
p4464
aS'Control CECMED'
p4465
aS'immunosorbent assay anti'
p4466
aS'exposure to hepatitis'
p4467
aS'X02763'
p4468
aS'nasally parenteral'
p4469
aS'individuals renal'
p4470
aS'group and one'
p4471
aS'careful performance'
p4472
aS'first vaccine dose'
p4473
aS'Biotechnology Havana Cuba'
p4474
aS'inflammatory Th1'
p4475
aS'exposure'
p4476
aS'recruited'
p4477
aS'71 in recipients'
p4478
aS'transparent liquid Each'
p4479
aS'first hour after'
p4480
aS'range 18'
p4481
aS'interest'
p4482
aS'first dose injection'
p4483
aS'immunogenicity in populations'
p4484
aS'volunteer generating'
p4485
aS'attributed'
p4486
aS'formal hypothesis testing'
p4487
aS'HBV infected patient'
p4488
aS'immunity elicited'
p4489
aS'over nasally'
p4490
aS'Following'
p4491
aS'prevent permanent impairment'
p4492
aS'responses against HBsAg'
p4493
aS'conditions occurred during'
p4494
aS'were fatal'
p4495
aS'administered through'
p4496
aS'recipients according'
p4497
aS'evident'
p4498
aS'immune compromised'
p4499
aS'Ethics Board'
p4500
aS'among individuals'
p4501
aS'signed'
p4502
aS'protein nature'
p4503
aS'wash and saliva'
p4504
aS'carriage'
p4505
aS'sterile saline solution'
p4506
aS'reporting specific post'
p4507
aS'treatment with blood'
p4508
aS'distribution'
p4509
aS'associated with functional'
p4510
aS'formulated with 50'
p4511
aS'display'
p4512
aS'4 9 Only'
p4513
aS'block'
p4514
aS'reported to elicit'
p4515
aS'rabbits'
p4516
aS'showing induction'
p4517
aS'measure'
p4518
aS'generating'
p4519
aS'Thirty days after'
p4520
aS'dose and sera'
p4521
aS'treatment group sample'
p4522
aS'were randomized'
p4523
aS'used as placebo'
p4524
aS'hematological'
p4525
aS'nasal vaccines currently'
p4526
aS'achieved antibody levels'
p4527
aS'CIGB production'
p4528
aS'attention Serious adverse'
p4529
aS'Briefly anti HBs'
p4530
aS'detect differences between'
p4531
aS'l seroprotection'
p4532
aS'43'
p4533
aS'volunteers without'
p4534
aS'anti HBs only'
p4535
aS'subjects showing antibody'
p4536
aS'Five'
p4537
aS'helpful'
p4538
aS'normal'
p4539
aS'individuals renal dialysis'
p4540
aS'30 one'
p4541
aS'6 13 excess'
p4542
aS'formulation Phase'
p4543
aS'15 minutes'
p4544
aS'body system'
p4545
aS'field of devices'
p4546
aS'had not achieved'
p4547
aS'infection Conversely'
p4548
aS'7 days post'
p4549
aS'primary outcome'
p4550
aS'screen failures included'
p4551
aS'recognize any local'
p4552
aS'adverse effects predominated'
p4553
aS'factors'
p4554
aS'persistent'
p4555
aS'minutes apart'
p4556
aS'B surface'
p4557
aS'HBs antibody were'
p4558
aS'analysis There'
p4559
aS'volumes'
p4560
aS'one subject'
p4561
aS'nasal immunogenicity'
p4562
aS'each rate percentages'
p4563
aS'infection or immunization'
p4564
aS'T cell immune'
p4565
aS'cell immune'
p4566
aS'responsiveness'
p4567
aS'major HBV antigens'
p4568
as.